4月19日（木） - convention.co.jp · 4月19日（木）...

47

19

106

1 41913:3014:001 SL1 YoshihiroMurata

1 4199:259:551 SEL1 DifferentiatingImmuneCheckpointInhibitorsforBladderCancers Joaquim BellmuntHarvard Medical School, USAIMIM-Hospital del Mar Medical Research Institute, Spain

2 41914:0014:301 SEL2 Immunotherapyforurothelialcancer:Currentstrategies,newdirections,andbiomarkerapproaches Jonathan RosenbergMemorial Sloan Kettering Cancer Center, USA

3 41914:4515:151 SEL3 UpdateofProstatePathology Lars EgevadKarolinska Institutet, Sweden

AUA / EAU / SIU 41911:1512:001 AllenChiuMedicalSchoolofNationalYang-MingUniversity,Taiwan AUA J. Brantley ThrasherUniversity of Kansas Health System, USA EAU Christopher Chapple Sheffield Teaching Hospitals NHS Foundation Trust / Honorary Professor, University of Sheffield /

Sheffield Hallam University / Secretary General, European Association of Urology, UK

SIU Patrick ColobyHospitalier Ren Dubos, France

UAA Lecture 41914:3014:451 Chi-WaiManTuenMunHospitalNewTerritory,HongKongUAA ThehistoryoftheUrologicalAssociationofAsiaanditsfutureperspectives MasaruMurai

AUA Lecture 1 4199:059:251 AUA1 ComplementaryandAlternativeMedicineinProstateCancer J. Brantley ThrasherUniversity of Kansas Health System, USA

AUA Lecture 2 4199:5510:151 Chi-WaiManTuenMunHospitalNewTerritory,HongKongAUA2 ComplicationsofUreteroscopy John DenstedtWestern University, Canada

Message from Asia 3 4198:05~9:051 Toward decline in prostate cancer mortality: PSA screening and prevention Wen-JengWuKaohsiungMunicipalTa-TungHospital,TaiwanMFA3-1 PSAscreening:wherearewegoing? Nicolas Mottet University Jean Monnet, FranceMFA3-2 PSAscreeninginJapan KazutoIto

48

19

The106thAnnualMeetingoftheJapaneseUrologicalAssociation

MFA3-3 ControversytoConsensus.ThedevelopmentofguidelinesforPSAtestingandtheearlymanagementoftestdetectedprostatecancer.TheAustralianExperience

Peter Heathcote President, Urological Society of Australia and New Zealand USANZ, AustraliaMFA3-4 LifestyleChangesandtheRiskofProstateCancer J. Brantley Thrasher University of Kansas Health System, USA

8 41910:15~11:151 Biology of urothelial carcinoma: new insights into molecular pathogenesis JianHuangSunYat-SenMemorialHospital,ChinaEL8-1 MolecularProfileofNon-InvasiveBladderCancer Margaret Anne Knowles University of Leeds, UKEL8-2 Patient-derivedorganoidmodelsofbladdercancer Michael M. Shen Genetics & Development, Urology and Systems Biology at Columbia University Medical Center, USAEL8-3 BiologyandClinicalApplicationofCancerTissue-OriginatedSpheroid MasahiroInoue

1 41915:3016:3013 EP1-1 HiroakiTakahashi EP1-2 TomonoriHabuchiEP1-3 HidetoshiUmemoto,

Up-to-Date 1 41915:30~16:304 Current advancements in understanding interstitial cystitis RogerRomanDmochowskiVanderbiltUniversityMedicalCenter,USAHann-ChorngKuoBuddhistTzuChiHospitalandTzuChiUniversity,TaiwanUD1-1 Interstitialcystitis/Bladderpainsyndrome:Americanviewpoint Philip Mark Hanno Stanford University School of Medicine, USAUD1-2 Urinemarkersofinterstitialcystitis AkiraFurutaUD1-3 Diagnosticandtherapeuticefficacyofnarrowbandimagingforulcer-typeinterstitialcystitis/

painfulbladdersyndrome MitsuruKajiwara

1 41915:2516:251 SY1-1 TreatmentGuidelinesforTesticularTumor:theSearchfortheEvidence Pilar LagunaAMC University Hospital Amsterdam, The NetherlandsSY1-2 KojiKawaiSY1-3 TerukazuNakamura,

49

19

106

2 41913:3014:304 JeanJacquesWyndaeleUniversityofAntwerp,BelgiumSY2-1 BasicResearchAspectsofRefractoryOveractiveBladder(OAB) Naoki YoshimuraUniversity of Pittsburgh, USASY2-2 ManagementStrategiesofNLUTDduetoSpinalCordInjury Helmut MadersbacherUniversity Hospital Innsbruck, AustriaSY2-3 PathophysiologyofRefractoryOveractiveBladderSyndromeClinicalAspects Hann-Chorng KuoBuddhist Tzu Chi General Hospital and Tzu Chi University, Taiwan

3 41914:3015:304 Underactive bladder RogerRomanDmochowskiVanderbiltUniversityMedicalCenter,USASY3-1 TheInternationalCURE-UABInitiative

(InternationalCongressofUrologicResearchandEducationonUnderActiveBladder) Michael B ChancellorBeaumont Health System, USASY3-2 UAB RyujiSakakibara SY3-3 UAB MinoruMiyazato

4 41916:3017:304 Focal therapy SY4-1 Focaltherapyforlocalisedprostatecancer Roland van VelthovenUniversit Libre de Bruxelles / Jules Bordet Institute, BelgiumSY4-2 Focaltherapy FumiyaHongoSY4-3 RFA KoichiroYamakado

5 41913:3014:305 VR / AR SY5-1 VirtualReality(VR) KazuhideMakiyamaSY5-2 AugmentedReality AtsuroSawadaSY5-3 VRAR KenjiYoshida

6 41914:3015:305 SY6-1 KazutoshiFujitaSY6-2 PSA TohruYoneyama

50

19


SY6-3 UrinomicsAnalysisforBiomolecularDiagnosisofProstateCancer KenjiNakayama

7 41916:3017:305 SY7-1 TomoyukiTakura SY7-2 MichioNojima SY7-3 JunjiUchida

8 41915:3016:306 SY8-1 :DOPPS,NationalDataBase ShunichiFukuhara SY8-2 LOHASSukagawa KenjiOmae , ,

9 41916:3017:306 SY9-1 AkihiroFuruta SY9-2 MotooArakiSY9-3 NobuyukiSekita

10 41913:3014:3013 SY10-1 TakashiFukagaiSY10-2 NaokiTeradaSY10-3 TakahiroKimura

Asia Urological Symposium 1 41914:15~14:553

RohanMalekSelayangHospital,MalaysiaAUS1-1 Roleofthebloodbasedbiomarkerindetectionofmetastaticprostatecancer Xin Gao The Third Affiliated Hospital, Sun Yat-Sen University, ChinaAUS1-2 Pitcher'sPotIlealNeobladder-Resultsof12yearsinover200patients Sudhir K Rawal Rajiv Gandhi Cancer Institute and Research Centre, India

51

19

106

AUS1-3 Androgenreceptorsignalingpathwayinhibitorsformenwithadvancedprostatecancer-whatwehaveknownin2018

Yeong-Shiau Pu National Taiwan University Hospital, TaiwanAUS1-4 FutureDirectionsinOABmanagement Peggy Sau-Kwan Chu Tuen Mun Hospital, Hong Kong


ManKayLiMtElizabethNovenaHospital,SingaporeAUS2-1 ESWL?isitdyinginthiseraofendourology? Anthony CF Ng SH Ho Urology Centre / The Chinese University of Hong Kong, Hong KongAUS2-2 Single-dockingRobotic-assistedNephroureterectomyandExtravesicalBladder-CuffResection

withoutIntraoperativeReposition:theTechniqueandtheOutcomes Chen Lyu Changhai Hospital, Hong KongAUS2-3 BCG:RelevantLessonsfortheClinicalApplicationofNewImmunotherapeuticAgents Kesavan Esuvaranathan National University Hospital / National University of Singapore, SingaporeAUS2-4 SurgicalDetailsandRenalFunctionafterRAPN Cheryn Song University of Ulsan College of Medicine, Asan Medical Center, KoreaAUS2-5 Peyronie'sDiseasein2018:Newtreatmentparadigmforanoldsexualdysfunctioncondition Eric Chung Andrology Centre / University of Queensland, Princess Alexandra Hospital, Australia


RajeevKumarAllIndiaInstituteofMedicalSciences,IndiaNarmadaPrasadGuptaMedanta,TheMedicity,IndiaAUS3-1 Acquireddown-regulationofBcellfunctionafterABO-incompatiblekidneytransplantation MasayukiTasakiAUS3-2 PostPCNLstonecultureasasinglepredictiveforpostoperativesepsis.Aprospectivestudyto

selectthepostPCNLpatientsantibiotictreatment Mohammad Hassan Alhamad Dubai Hospital / Dubai Health Authority, UAEAUS3-3 AlteredRNAsplicingbySFXpromotesmalignancyinprostatecancer NorihikoKawamuraAUS3-4 Evolutionofroboticsurgery:IndianPerspective Girdhar S Bora Post Graduate Institute of Medical Education & Research, IndiaAUS3-5 Molecularpathogenesisofclearcellrenalcellcarcinomaandcortisol-producingadrenaladenoma YusukeSatoAUS3-6 TheroleofmpMRIinimprovingtheaccuracyofprostatebiopsy Guan-Hee Tan Universiti Kebangsaan, Malaysia

Debate 1 41915:3016:305 Total cystectomy : To do? , or Not to do? DB1-1 YoshiyukiMatsuiDB1-2 TeruoInamoto

52

19


26 41911:0011:202 MotohideUemura

11 41911:2012:002 AL-1 SatoruTaguchiAL-2 CRISPR/Cas9

MasayaYonemoriAL-3 Androgenreceptorsplicingvariant7

NorihikoKawamuraAL-4 Transmembraneprotein2TMEM2

HayatoYamamotoAL-5

ToshikiEtani

1 4198:209:402 AVP-01 Evaluationofbladderfunctionusingdetrusormomentum ShigehiroSohAVP-02 Theeffectivenessofindocyaninegreen(ICG)useforthequalityimprovementtoextentedpelvic

lymphadenectomyduringRARP MasakiShimboAVP-03 Candiffusionweightedwholebodyimagingwithbackgroundbodysignalsuppressiondetect

metastasisofprostatecancerduringatearlystage? YukiShimizuAVP-04 Fluiddynamicalassessmentoflowerurinarytract:exploratoryresearchtoobservevorticityin

prostaticurethrausingcolordopplerultrasonography TomonoriMinagawaAVP-05 Real-timetransrectalultrasoundnavigationduringrobot-assistedlaparoscopicradical

prostatectomy TakumiShiraishiAVP-06 Head-mounteddisplayassistedMRI-USelasticfusionprostatebiopsysystem ShoUehara

2 4199:4011:002 AVP-07 Whatistheeffectivenessinsurgicalnavigationwiththeautomatictrackingsystemautomatedfor

robot-assistedpartialnephrectomy? SatoshiKobayashi

53

19

106

AVP-08 Single-surgeonseriesofdelayedurethroplastyforpelvicfractureurethralinjury:experiencein100patientsduringthelast10years

AkioHoriguchiAVP-09 Establishmentoftreatmentstrategiesforimpactedcalculibyanalyzingtheureteroscopicfindings

inTUL ShuzoHamamoto, SMART Study GroupAVP-10 Laparoendoscopicsingle-siteureteralreimplantationforvesicoureteralreflux WataruSakamotoAVP-11 Anovelprocedureofurinarytractsuturingtopreventpostoperativeurinaryfistulainlaproscopic

partialnephrectomy NobuyukiFukuzawaAVP-12 ComparisonofstandardPNLandECIRSinthemodifiedlateralpositionusingthepressure-

controlledperfusatesupplysystemforstonedelivery DaisukeKudo

1 4199:0010:003 AOP-001 WT1-specificcytotoxicTlymphocytesregeneratedfromTcell-derivediPScellsexerttherapeutic

effectinWT1-expressingrenalcellcarcinoma SokiKashima ,AOP-002 Characterizationofcryoablation-inducedimmuneresponseinkidneycancerusingTcellreceptor

sequencing TaigoKatoAOP-003 Targetingmetabolismre-programmingasatherapeutictargetfordrugresistanceinrenalcell

carcinoma HirofumiYoshinoAOP-004 Superoxidedismutase2expressioncanpredictprognosisofmetastaticrenalcellcarcinoma TetsuyaYoshidaAOP-005 InflammationamplifierasamechanismofTKIresistanceonrenalcellcarcinomacells KeiIshibashiAOP-006 Mutationsinthemitochondrialgeneareassociatedwithpostoperativeprognosisoflocalizedrenal

cellcarcinoma HakushiKimAOP-007 Explorationofthebiomarkerscontributingtoprognosticpredictioninclearcellrenalcell

carcinoma KeitaTamura, AOP-008 miR-194-5pdown-regulatedlysosomeassociatedmembraneprotein2relatedtosunitinib

resistanceinrenalcellcarcinomacells TetsuyaYumiokaAOP-009 ERK5inhibitionasapotentialtherapeutictargetforclearcellrenalcellcarcinoma HidenoriKannoAOP-010 CorrelationoftheinsulinreceptorexpressionchangesbytheadministrationofVEGFR-TKIandthe

resistancetotheVEGFR-TKIinclearcellrenalcellcarcinoma MasayukiTakahashiAOP-011 Ananalysisofphosphatidicacidforclearcellrenalcellcarcinoma NoriakiUtsunomiya

54

19


2 41910:0011:003 AOP-012 Clinicalimplicationsoftherapeuticdrugmonitoringsandgeneticpolymorphismsonthe

pharmacokineticsofsunitinibinmetastaticrenalcellcarcinomapatients KazuyukiNumakuraAOP-013 Multicenterstudyofpathologicalandprognosticfindingsinnon-clearcellrenalcellcarcinoma HiroakiMatsumoto, AOP-014 Acutekidneydiseaseafterpartialnephrectomy:impactofischemicareacalculatedbythe

computationalimaginganalysis ShujiIsotaniAOP-015 MeaningandsignificanceoflowdensityareaofrenaltumorsonCT KeitaShibayama, AOP-016 Survivalamongpatientswithmetastaticrenalcellcarcinomainthepretargetedversustargeted

therapyerasinarealclinicalsetting ToshinariYamasakiAOP-017 Theimpactandriskfactoroftoxicperirenalfatinrobotassistedpartialnephrectomy NaohikoFukamiAOP-018 ImpactofmorphologicalfeaturesofclinicalT1renalcellcanceronthepredictionoftheupstaging

topathologicalT3orhigher JunTeishimaAOP-019 Increasedconcentrationandshortnessofcirculatingcell-freeDNAcouldbeadiagnosticand

prognosticmarker,respectivelyinclearcellrenalcellcarcinoma YoshiyukiYamamotoAOP-020 Contrastmediaenhancementreductionpredictstumorresponsetopresurgicalmolecular-targeting

therapyinpatientswithadvancedrenalcellcarcinoma ShogoHosogoeAOP-021 EarlyassessmentwithFDG-PET/CTtopredictshort-termoutcomeinclearcellrenalcarcinoma

treatedwithnivolumab TadashiTabei,

3 41911:0011:503 AOP-022 Classicalcomplementpathwayactivationmechanismingrowthprocessofbenignprostatic

hyperplasia.-autoimmuneresponsebyfetalantigen- JunyaHataAOP-023 Highluteinizinghormoneweakensurinarycontinencemechanismsinassociationwith

prostaglandinE2elevationinapostmenopausalratmodel TomohiroEriguchiAOP-024 Themechanismsunderlyingcoolinginducedcontractionindetrusorsmoothmuscleinvolves

neitherTRPA1orTRPM8 TomokoMakiAOP-025 Humanskeletalmuscle-derivedstemcellsrepairtheratdamagedurethrawithparacrineeffect NobuyukiNakajima AOP-026 Theurotheliumofurinarybladderplaysanessentialroleasanimmunosensoragainstbacterial

urinarytractinfection NorichikaUeda ,

55

19

106

AOP-027 UrethraldysfunctionandtherapeuticeffectsofaPDE5inhibitor(Tadalafil)inaratmodelofneurogenicunderactivebladderinducedbypelvicnervecrush

Ei-ichiroTakaoka, AOP-028 EffectofInsulin-likegrowthfactor1sustained-releasecollagenurethralstentonpreventionof

urethralstrictureafterurethralinjuryinaRabbitmodel MasayukiShinchi

4 4199:0010:009 AOP-029 Systematicchemicalscreeningidentifiesdisulfiramasarepositionabledrugthatenhances

sensitivitytoCDDPinbladdercancer YukiKitaAOP-030 Developmentofliposomeincorporatingketo-mycolicacidderivedfromBCGcellwallfortreatment

ofbladdercancer TakayukiYoshinoAOP-031 AberrantN-glycosylationprofileofserumimmunoglobulinsisadiagnosticbiomarkerofurothelial

carcinomas ToshikazuTanakaAOP-032 AdaptorproteinCRKregulatesErbB2expressioninexosomeandpromotestumorprogressionand

metastasisofbladdercancer KazuhikoYoshida, AOP-033 Geneticlandscapeandclonalexpansionofupperurinarytracturothelialcarcinoma YoichiFujii, AOP-034 CombineduseofstandardanticanceragentsincreasesthecytotoxicityofhumanTcellinin

vitroandin vivoinbladdercancer TerukiShimizu , AOP-035 NOTCH2over-expressioninthebladderpromotestumordevelopmentandleadstomoremalignant

phenotype AkihiroGorikiAOP-036 IncreasedABCB1expressionintumorbloodvesselsofurothelialcarcinomaafterchemotherapy HiroshiKikuchi , AOP-037 Panobinostatandmetformininhibitbladdercancergrowthbyinducinghistoneacetylationand

endoplasmicreticulumstressviaactivatingAMPK KazukiOkuboAOP-038 Investigationonanti-cancereffectsof4N1K-peptidederivedfromthrombospondinsinintravesical

therapyforbladdercancer YasuyoshiMiyata

5 41910:0011:009 AOP-039 ClinicaloutcomeofsubsequentnonmuscleinvasivebladdercancertreatedbyintravesicalBCGin

patientswithupperurinarytracturothelialcarcinoma MakitoMiyakeAOP-040 Evaluationofthesafetyandshorttermpathologicaleffectsofchemoradiationtherapyinpatients

withbladdercancer:amulticenterprospectivetrial NaokazuIbuki

56

19


AOP-041 Regionaldistributionoflymphnodemetastasisinupperurinarytracturothelialcancer,sub-analysisoflargemulti-institutionalstudy(JCOG1110A)

JunichiInokuchi, JCOGAOP-042 Initialexperienceofprobebasedconfocallaserendomicroscopyusingacrinolandfluorescein

duringTURBT-visualisingofcancercellnuclei- YoshioNaya, AOP-043 Preoperativenomogramforpredictinglocallyadvanceddiseaseofupperurinarytracturothelial

carcinoma TakashiYoshidaAOP-044 Evaluationofdiagnosticabilityinpreoperativediagnosisofuppertracturothelialcarcinoma

-ComparisonofurinecytologyandUroVysion- NaotoSassaAOP-045 Oncologicaloutcomesofneoadjuvantchemotherapyinpatientswithlocallyadvanceduppertract

urothelialcarcinoma:Amulticenterstudy YukaKubota, AOP-046 Theclinicalroleofpurifiedproteinderivativeskintestinpatientswithnon-muscleinvasivebladder

cancertreatedwithadjuvantbacillusCalmette-Gurin NaoyaNiwa, AOP-047 Treatmentoutcomeoflaparoscopicradicalcystectomy:multicenterstudy ToruKannoAOP-048 OncologicaloutcomeofclinicalT1bladdercancersub-stagingandefficacyofEn-blocTUR

specimen TakafumiYanagisawa

6 41911:0011:509 AOP-049 Antioxidantpolymerprodrugsattenuatesrenalgraftdysfunctionaftersyngeneicrenal

transplantation KoichiroMinamiAOP-050 Therapeuticstrategyforlongtermgraftsurvivalinkidneytransplantation:Riskfactorsrelatedtoan

increaseofinterstitialfibrosisinthekidneygraft MitsuruSaitoAOP-051 HereditarykidneydiseasemodelingincynomolgusmonkeysusingCRISPR/Cas9injectioninto

ICSIembryos KenichiKobayashi, AOP-052 Urinaryorosomucoid1(ORM1)couldbeanearlydiagnosticbiomarkerandatherapeutictargetfor

chronicrejectionafterkidneytransplantation HarukaHiguchi , AOP-053 Theevaluationofantigen-specificIgMandIgGproductionintheperipheralbloodmononuclear

cellsagainsttheantibody-mediatedrejection RyoichiImamuraAOP-054 Theimpactofglomerularbasementmembranethickness(GBMT)onpostoperativerenalfunction

inlivingkidneydonors ShingoHatakeyamaAOP-055 Relatedfactorsofsarcopeniaanditscountermeasureinkidneytransplantrecipients MasaakiYanishi,

57

19

106

AOP-056 Utilityofdutasterideformaledialysispatientswithbenignprostateenlargement TomohiroMagari

7 4199:0010:0010 AOP-057 HSP70inhibitorssuppressandrogenreceptorsplicevariant7(AR-V7)expressionincastrate

resistantprostatecancercelllines kazuakiKitaAOP-058 Semaphorin3Cdrivescancergrowthandtreatmentresistanceviacognateligand-independent

activationofmultiplereceptortyrosinekinases ArioTakeuchiAOP-059 Uc.63+promotesresistancetodocetaxelthroughandrogenreceptorsignalingandapromising

serumbiomarkerfordocetaxeltreatmentinprostatecancer YoheiSekino , AOP-060 Luteolinhasprotectiveroleforcastration-resistantgrowthinprostatecancer TakuNaiki AOP-061 High-fatdiet-inducedinflammationacceleratestumorprogressionviaIL6signalinginmicemodel

forprostatecancer TakujiHayashiAOP-062 IdentificationoffourteennewsusceptibilitylociforprostatecancerintheJapanesepopulation RyoTakataAOP-063 Developmentofcombinationalcancerimmunotherapycomprisingoralprostatecancervaccineand

anti-PD-1antibody ToshiroShirakawa,AOP-064 ChemopreventiveeffectsofAngiotensinIIreceptortype2agonistonprostatecarcinogenesis HirojiUemuraAOP-065 Noveltherapytargetingandrogenreceptorsplicevariantsbyinhibitingheatshockfactor1(HSF1)

forthetreatmentofcastration-resistantprostatecancer ToshikiKijimaAOP-066 Exploringthebiologicalmechanismbywhichthedeletionofmale-specifichistonedemethylase

JARID1DcausesDNAreplicationstressinprostatecancer KazumasaKomura, AOP-067 AndrogenenvironmentandexpressionofandrogenreceptormessengerRNAinperipheralbloodin

patientswithadvancedprostatecancer KoheiInui

8 41910:0011:0010 AOP-068 Androgenreceptorgeneaberrationincirculatingcell-freeDNAfromcastration-resistantprostate

cancer TakayukiSumiyoshiAOP-069 Impactofneoadjuvantandrogendeprivationonthepatternofbiochemicalfailureafterradical

prostatectomy KazuhiroMatsumotoAOP-070 ClinicalsignificanceofMRI-targetedbiopsyfortheriskstratificationofoncologicaloutcomeafter

radicalprostatectomy YohMatsuoka

58

19


AOP-071 AutomateddiagnosisofprostatecancerlocationbyartificialintelligenceinmultiparametricMRI YuichiroOishi, AOP-072 UsefulnessofthemodifiedGlasgowPrognosticScore(mGPS)inpatientswithcastration-

sensitiveprostatecancer:muti-institutionalstudy JunpeiIizukaAOP-073 TheexpressionofPSMAincirculatingtumorcellsasapredictivemarkerforpoortreatment

responseincastration-resistantprostatecancer NaoyaNagayaAOP-074 Developmentoflectin-antibodyELISAkitofurinaryCore-typefucosylatedPSA:anewbiomarker

forhighriskprostatecancer KazutoshiFujita AOP-075 AnalysisoftheclinicalpredictivefactorsforthedetectionofsignificantcancerwithMRI-TRUS

fusionimage-guidedprostatebiopsy SunaoShojiAOP-076 Theinfluenceofhemi-glandpositiveMRIonnegativesidesprostatecancerdetection YasukazuNakanishiAOP-077 Evaluationofhemoglobindynamicsinrelationtoefficacyofsecond-generationanti-androgensin

patientswithcastrate-resistantprostatecancer TeruoInamoto

9 41911:0011:5010 AOP-078 Aselectivelysine-specificdemethylase1inhibitorsuppressesgermcelltumorproliferation ToshikiEtaniAOP-079 Putativedevelopmentofaldosteroneproducinglesionsshownbystate-of-the-artMALDIimaging KoshiroNishimoto, AOP-080 Contralateraladrenalwidthpredictsthedurationofprolongedpostsurgicalsteroidreplacement

forsubclinicalCushingsyndrome YusukeImamuraAOP-081 Analysisinfunctionofandrogeninseminoma TakashiUeda, AOP-082 Efficacyoflaparoscopicadrenalectomyforpatientswithprimaryaldosteronismwithlowerleft

ventricularejectionfraction ShinSatoAOP-083 Treatmentoutcomeofpatientswithextragonadalgermcelltumors:singleinstituteexperience AkiraNagahara AOP-084 Prognosticfactoroflaparoscopicsurgeryagainstmetastaticadrenaltumors TakayukiGotoAOP-085 UrachalcarcinomainKyushu-Okinawaarea:Diagnosis,management,andprognosis KazumaUdoAOP-086 Inductionofoscillationmodelforthemotionofarterialwallinpheochrmocytoma TakaoKamai

59

19

106

10 4199:0010:0013 AOP-087 TheImpactofintraductalcarcinomaoftheprostateonagradegroupsystemofprostatecancer MasashiKatoAOP-088 ProstatespecificantigenbounceafterpermanentIodine-125implantbrachytherapy:Nationwide

J-POPSmulti-institutionalprospectiveCohortStudy TakefumiSatoh ,125

J-POPS

AOP-089 Theimpactofextendedlymphnodedissectionversusneoadjuvanttherapywithlimitedlymphnodedissectioninhigh-riskprostatecancerpatients

TakumaNaritaAOP-090 ImprovedsurvivalofmenwithM1prostatecancertreatedwithandrogendeprivationtherapyplus

prostaticradiotherapy.Apropensityscore-matchedanalysis AkihiroYanoAOP-091 Optimalandrogendeprivationforthepatientsundergoinghigh-dose-ratebrachytherapy-Results

fromnationwidemulticenterretrospectivestudy AkiraKomiya, AOP-092 Prospectiveevaluationofeffectonintraocularpressureandvisualfunctioninpatientsundergoing

roboticassistedlaparoscopicprostatectomy ShigenoriKakutani, AOP-093 EfficacyofCarbon11-cholinepositronemissiontomography/computedtomography-guidedlocal

treatmentinpatientsofcastration-resistantprostatecancer TaroTeshimaAOP-094 Developmentandvalidationofanovelprognosticmodelforpredictingoverallsurvivalintreatment

navecastration-sensitivemetastaticprostatecancer MasashiKubota AOP-095 Salvagecryoablationtargetingrecurrentlesionsafterdefinitiveradiotherapyforprostatecancer KentaMiki

11 41910:0011:0013 AOP-096 Whole-transcriptomeprofilingininterstitialcystitisandrelativediseasesbynext-generation

sequencing:Aparadigmshiftofthediseaseconcept YoshiyukiAkiyamaAOP-097 ThenumberoffactorsformetabolicsyndromeistheriskfactorfordenovoOABafterpelvicorgan

prolapserepair MasaoKataokaAOP-098 Primaryrealignmentforstraddleinjurytotheanteriorurethraisassociatedwithprolongedtimeto

urethroplastyandincreasedstricturecomplexity KenichiroOjimaAOP-099 Metabolomicsapproachfornocturiainagedmen:aninvestigationofpossiblebiomarkersand

targetsfornewtreatments SatoruKiraAOP-100 Newevaluationindexofbladderimageinchildrenwithmyelomeningocele:Isthevertical/

horizontalratiousefultoexpecturodynamicparameters? YoheiKumano

60

19


AOP-101 RetorospectiveanalysisfocusingonsymptomchangeandclinicaloutcomesinfemalepatientswithOAB

AtsukoFujiharaAOP-102 Long-termtreatmentforoveractivebladderofelderfemalesmayreducethefearforfalls MitsuruKajiwaraAOP-103 InsomniamakesLUTSworse:AlongitudinalstudyofNagahamacohort ArinobuFukunagaAOP-104 Associationofnocturia,sleepdisorder,andqualityoflifeincommunity-dwellingpopulation:

ResultsfromIwakihealthpromotionprojectinJapan AyumuKusakaAOP-105 SignificanceofC-reactiveproteinasaninflammatorymarkerinpatientswithinterstitialcystitis TomohiroMatsuo

12 41911:0012:0013 AOP-106 Risk-relatedgenesforhypospadiasbySNPanalysisinJapaneseaffectedtheurethral

development TomoyukiKoguchiAOP-107 DiagnosisandtreatmentofBBDissuperiortothoseofVURforfebrileUTI

recognizedinyounggirls ShinaKawaiAOP-108 BenefitofnavigationsurgeryapplyingBio-TextureModelingandVR/AR/MRinurology YoshiyukiShigaNTTAOP-109 Retroperitoneallaparoscopicsurgerytosalvagefromurinarytractproblems MasahikoSatoAOP-110 Ambienttemperatureandmidnighttoearlymorningperiodonsetarepredictorsoftesticulartorsion

amongacutescrotums.Aprospectiveobservationalstudy HidekiTakeshitaAOP-111 Clinicalimplicationofasimplequantitativefrailtyassessmenttoolforprognosisinpatientswith

urologicalcancers OsamuSomaAOP-112 Neourethralobstructionisastrongriskfactorofinfertilityinhypospadiaspatients AkihiroKanematsuAOP-113 InvestigationofgeneticvariationrelatedtosymptomseverityinJapanesetuberoussclerosis

patients HitomiSasakiAOP-114 Experimentalstudyforanewadhesion-preventionagentafterlaparoscopicsurgeryofrabbitmodel YasuyukiNaitoh

13 4199:0010:0014 AOP-115 Inducedhormone-producingLeydigcellsderivedfromhumaniPScells TakakiIshida , iPSAOP-117 Developmentofspermsearchingsystemusingartificialintelligenceinassistedreproductive

technology TeppeiTakeshima

61

19

106

AOP-118 Effectoftissuesealingsheetonerectiledysfunctionfollowingrobotic-assistedlaparoscopicprostatectomy:Interimresultsofarandomizedcontrolledtrial

ShinichiYamashitaAOP-119 IsolationoftesticularsomaticcellsusingDSAlectinandpercollmethods SatoshiNozakiAOP-120 Anewpeniletumescenceandhardnessmonitoringdevice,itsdesignconceptandprototyping SeijiMatsumotoAOP-121 Intravenousinfusionofmesenchymalstemcellsreduceserectiledysfunctionfollowingcavernous

nerveinjuryinrats YoheiMatsudaAOP-122 DecreasedexpressionofP-typeATPaseinpubertalratcryptorchidtestisanditsrelationtothermal

environment ShoichiroIwatsukiAOP-123 Riskfactorsforage-relatedchangeinerectiledysfunction:acommunity-basedandlongitudinal

studyinJapan AtsushiImaiAOP-124 Effectoforaladministrationofpolyaminefortesticulardamageinmiceandswine TatsuyaTakayama

14 41910:0011:0014 AOP-125 Themechanismofpreventionofurinarystonebywhiteadipocytetobeigecelltransdifferentiation TeruakiSuginoAOP-126 Nextgenerationsequenceelucidatesanovelmechanismforcalciumoxalatestonedevelopment:

lipidmetabolismviaFattyAcidBidingProtein4 KazumiTaguchi, , AOP-127 EstablishmentofNovelGeneticDiagnosticClassificationThatReflectsSeverityofCystinuria ShinichiSakamotoAOP-128 IncreasesinMycoplasma genitaliumwithmultidrug-resistanceinJapan ShinItoAOP-129 SelectiveautophagyviamTORC1andTFEBsignalssuppresseskidneystoneformation ReiUnnoAOP-130 Initialevaluationmethodsforsepsisofacutepyelonephritiscausedbycalculitreatedwithureteral

stent ShotaroWatanabeAOP-131 Theroleofindoleamine2,3-dioxygenaseIDOinprostatitis ShinOhiraAOP-132 Clinicalpharmacokineticsofbeta-lactamandquinoloneinprostatetissue,anddosing

considerationsforprostatitisbasedonsite-specificpharmacodynamics KogentaNakamuraAOP-133 Trendsofquinoloneresistantand/orESBLproducingEscherichia coliinurinarytractinfections YoshitsuguNasu

62

19


JUA/UAA Oral 1 41913:3014:308 Urothelial tumors, biology, UTUC IS-01 NOTCH2-HEY1axispromotestumorprogressioninbladdercancerthroughcellcycleprogression

anddedifferentiation Tetsutaro HayashiUniversity of Hiroshima, Hiroshima, Japan, Vancouver Prostate Centre, Vancouver, CanadaIS-02 Precisionmedicine-orientedestablishmentandpathological/biochemicalanalysisofPDX

(Patient-derived-xenograft)ofurothelialcancer Ryoichi SaitoKyoto University Hospital, Kyoto, JapanIS-03 Retrogradepyelographybeforeradicalnephroureterectomyforupperurinarytracturothelial

carcinomaaggravatesintravesicaltumorrecurrence Young Hwii KoYeungnam University, Hyunchung-ro, KoreaIS-04 Thediagnosticureteroscopybeforeradicalnephroureterectomyinupperurinarytracturothelial

carcinomaisnotassociatedwithhigherintravesicalrecurrence Hsiang ying LeeKaohsiung Municipal Ta-Tung Hospital, Kaohsiung, TaiwanIS-05 Thediagnosisofcarcinomainsituoftheupperurinarytractshouldbereconsideredtoavoid

overtreatment Motoo Araki Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JapanIS-06 Outcomeofmaintenancesystemicchemotherapywithdrug-freeintervalformetastaticurothelial

carcinoma Takashige AbeHokkaido University Hospital, Hokkaido, JapanIS-08 Degradablenanoagentsforphotothermal-chemotherapyofcervicalcancercellandbladdercancer

cell Yichun ChiuDepartment of Applied Chemistry, National Pingtung University, Taipei, Taiwan

JUA/UAA Oral 2 41914:3015:308 Male LUTS & gerontology AlexLinTaiepeiVeteransGeneralHospital,TaiwanJeJongKimKoreaUniversity,SouthKoreaIS-09 ClinicalInvestigationofHomecareUrologyinaJapaneseHomecareSupportClinic Satoshi YazawaYazawa Clinic, Saitama, JapanIS-10 Impairmentintheactivityofdailylivingamongelderlyreceivingmajorsurgeriesforurological

malignancy Toru SugiharaTokyo Metropolitan Tama Medical Center, Fuchu, JapanIS-11 TheCharacteristicsofAutonomicActivityinMenwithLUTSandSleepApnea Jong Bo ChoiAjou University Hospital, Yeongtong-gu, KoreaIS-14 Therelationshipoftestosteroneandlowerurinarytractsymptomsafterwithdrawingdutasteride Mamoru HashimotoKindai University, Osaka, JapanIS-15 Multi-pulseLaserVaporesectionVersusBipolarTransurethralResectionoftheProstate:

ComparativeClinicalExperience Fu-Shun HsuNew Taipei City Hospital, Taipei, TaiwanIS-16 Combinationofthuliumlaserincisionandbipolarresectionoffersbetterefficiencyinendoscopic

prostatectomy:Anovelthuliumlasertechniquepresentation Kuan Chun HuangMackay Memorial Hospital, Taipei, Taiwan

63

19

106

JUA/UAA Oral 3 41915:3016:308 Prostate cancer, screening, diagnosis, localized EdmundChiongNationalUniversityHealthSystem,SingaporeIS-17 A21-yearfollow-upstudyofprostatecancercasesdiagnosedbycommunity-basedPSAscreening

thatmettheJapaneseActiveSurveillancecriteria Koji OkiharaKyoto Prefectural University of Medicine, Kyoto, JapanIS-18 Multiparametricmagneticresonanceimaging-transrectalultrasoundfusionprostatebiopsywith

elasticfusion:aprospectivestudyintheChinesepopulation Wai Kit MaDepartment of Surgery, the University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong KongIS-20 Thevalueofprostatehealthindextopredictmagneticresonanceimaginglesionsinmenwith

clinicalT1stageprostatecancerduringactivesurveillance Yung-Ting ChengNational Taiwan University Hospital, Taipei, Taiwan (R.O.C)IS-21 Transrectalprostatebiopsysepsisratefollowingreducedquinoloneantibioticprophylaxisfromsix

dosesoverthreedaystosingledose Haider Khan BangashFIona Stanley Hospital, Perth, Australia.IS-22 PostivesurgicalmarginwithbiochemicalrecurrenceratesafterradicalprostatectomyinSiriraj

hospital:asinglecenterexperience Varat WoranisarakulDepartment of Surgery, Siriraj Hospital, Mahidol University, Bangkok, ThailandIS-23 Therapeuticselectionforpatientwithveryhighriskprostatecancer:asinglecenterexperience Cheng Hsin LuE-Da Hospital, Kaohsiung, Taiwan

JUA/UAA Oral 4 41916:3017:308 Prostate cancer, advanced, experimental ChuyenVuLeBinhDanHospital,VietnamTonyWuKaohsiungVeteransGeneralHospital,

Taiwan

IS-25 circPRKG1targetpTENtoinductprostatecancercellsproliferationandmigrationbyspongingmiR-21andmiR-153

Haoqing ShiShanghai Changhai Hospital, the Second Military Medical University, Shanghai, ChinaIS-26 Androgenreceptorsin3Dco-culturedhumanprostatestromalcellsregulatedprostatestromal-

epithelialdirectcell-cellinteractionandglandularformation Shauh-Der YehTaipei Medical University Hospital, Taipei, TaiwanIS-27 HighexpressionofserumWnt5Bisanovelpoorprognosticbiomarkerinmetastaticprostate

cancer Sayuri TakahashiThe University of Tokyo, Tokyo, JapanIS-28 AKR1C3,asanoveltargetofDAB2IPsignaling,maintainstheproteinstabilityofandrogen

receptorsplicingvariantinprostatecancer Kaijie WuFirst Affiliated Hospital of Xi'an Jiaotong University, Yanta West Road, ChinaIS-29 Survivalbenefitofcabazitaxelincastration-resistantprostatecancerpatientspredictedwithpoor

prognosis Kohei HashimotoSapporo Medical University, the Sapporo Medical University Urologic Oncology Consortium, Sapporo, JapanIS-31 EffectsofStatinonDementiainPatientswithAndrogenDeprivationTherapyforProstateCancer Jui-Ming Liu Department of Surgery, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan, National Yang-

Ming University, Taipei, Taiwan,Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan

IS-32 Neutrophil-tolymphocyteratio(NLR)wouldbepredictorincastrationresistantprostatecancertreatedbyenzalutamideorabirateroneacetate

Takashi KawaharaYokohama City University Medical Center, Yokohama, Japan

64

19


1 41914:3015:309 VP-01 HidejiKawanishiVP-02 TUL TakahiroIchimi VP-03 f-TUL1 GoAnanVP-04 Nd&Ho:YAG SoichiMugiyaVP-05

KazunobuShinoda,VP-06 KazuyoshiIzumi

2 41915:3016:309 VP-07 ShukoHonda,VP-08 RSC() TokikoNiimuraVP-09 TVT AkikoFujisakiVP-10 KoichiNagaoVP-12 FumitakaKoga

3 41916:3017:309 VP-13 HoLEP GoAnanVP-14 HoLEPUrodynamic4D-CT ShintaroMoriVP-15 -- KiyotakaKawashimaVP-16 Fullfunctional-lengthurethralsphincterAP-HoLEP FumiyasuEndoVP-17 ONCO-TESE KazutakaTerai

1 41913:3014:309 OP-001 Androgenreceptor MasahiroSugiura

65

19

106

OP-002 FOXA1AR HiroakiSato, OP-003 Full-lengthandrogenreceptor(AR)ARsplicingvariant

invitro YoheiShidaOP-004 HirotsuguUemuraOP-005 PTEN MarcoDeVelascoOP-006 PD-L1 NobutakaShimizuOP-007 PTENAKTPim

YurieKuraOP-008 MototaroIwanaga

2 41913:3014:3010 OP-009 IPSS ToshikiOkaOP-010 RALP YusukeInagakiOP-011 continencerecovery MichioShiozawaOP-012

TotalAnatomicalReconstruction YoshioSuginoOP-013

KimihikoMasuiOP-014 MRI MasahiroSamotoOP-015 PSAQOL HarukaMiyaiOP-016 PatientReportedOutcome KatsuyoshiHashine

3 41914:3015:3010 OP-017 ToshifumiKurahashiOP-018 3 JunNakashima, ,

66

19


OP-019 (RARP) KosukeKitamuraOP-020 PSA ToshiyukiChinaOP-021 RyoTanjiOP-022 Urodynamicstudy AkioTsutsuiJCHOOP-023 (HoLEP)

(RALP) HiroakiShimmuraOP-024 Ver.2 IchiroYoshimura

4 41915:3016:3010 OP-025 RALPLRP IsaoTaguchiOP-026 RyosukeJikuyaOP-027 TaiyoOtoshiOP-028 Parallelsidedocking

ToshihiroUemuraOP-029 200 TakashiImamotoOP-030 EndoWristStapler45DVC(RARP) MasashiInuiOP-031 RALP

MitsunoriMatsuoOP-032 500 NaotoMiyajima

5 41916:3017:3010 OP-033 KazutoChibaOP-034 TakuyaOkadaOP-036 -RARP- MasakiShimbo

67

19

106

OP-037 CK

AkifumiOnagiOP-038

ShinichiHisasueOP-039 (RARP) KazuyoshiKoOP-040 KazushiTanaka

6 41913:3014:3011 OP-041 (NLR) YukiMaruyamaOP-042 YosukeMitsuiOP-043 MasanobuShigaOP-044 69 AkiyukiYamamotoOP-045 NorikataTakadaOP-046 TerukazuNakamuraOP-047 YoshieKanadaOP-048 purehepatoidvariant NaotoHodotsuka

7 41914:3015:3011 OP-049 MasakiKimuraOP-050 KojiShiraishiOP-051 1 HidetakaSuzukiJCHO OP-052 HidenoriIwai OP-053 9 NaokoHonmaOP-054 3 KeitaKawashiro

68

19


OP-055 endovascularrevascularization YasuoKawanishiOP-056 1 ManabuKawano

8 41915:3016:3011 OP-057 ESBL KenjiKawamuraOP-058 1 YuichiroHishikawaOP-059 OkamuraTakehikoOP-060 SeisukeNofujiOP-061 TakanobuYamamotoOP-062 5 YosukeMatsutaOP-063 MitsuhiroTamboOP-064 RyoOka

9 41916:3017:3011 OP-065 KuriAokiOP-066 UPJO50 ManabuIchinoOP-067 10 HiroyukiSatohOP-068 1310 YasuhiroKoikawaOP-069 MadokaHiguchiOP-070 CIC ShoheiTobuOP-071 KazuyoshiJohnin

10 41913:3014:3014 OP-072 RALPpT3 YukiMiyauchi

69

19

106

OP-073 RARPClinicalT3 MamoruFukudaOP-074 MRI NoriyaYamaguchiOP-075 ShuichiMorizaneOP-076 (RALP)(NS) TakuroSunadaOP-077 NobuyoMoritaOP-078 TerutakaNoda

11 41914:3015:3014 OP-079 TURPHoLEP YasuoUedaOP-080 30WHoLEP400 SatoshiYotsuyanagiOP-081 HoLEP ShinKumagaiOP-082 HoLEP KazukiMasudaOP-083 QuantaLithoHoLEP KojiFukuiOP-084 HoLEP JunryoRiiOP-085 enbloc ShuichiroKobayashiOP-086 HoLEPKHQ KeiOmori

12 41915:3016:3014 OP-087 PVP1500 YoshitakaKuwaharaOP-088 2ndPVP SusumuWatanabeOP-089 PVP5 AkitoYamaguchi,PVPOP-090 75PVP ShizukaIidaOP-091 ContactlaserVaporizationoftheProstateCVP)

ShinobuKato

70

19


OP-092 CVP NobuoTsuruOP-093 CVPContactlaserVaporizationoftheProstate YoshihiroKomai

13 41916:3017:3014 OP-094 OfficeUrology19TUEBBNS

HiroshiMitaniOP-095 HERRMANN/CUBE KenzoNakamura OP-096 TUEB YujiKatoOP-097 (TUEB) KenjiKawamuraOP-098 TUEBtransurethralenucleationwithbipolar

1 YasuyukiKobayashiOP-099 ToruHasegawaOP-100 (ThuVAP)

MitsuruKohnoOP-101 Thuliumlaserenucleationoftheprostate(ThuLEP) IzumiHanada

14 41913:3014:3015 OP-102 T1b-2N0M0 MasanobuShigetaOP-103 TakahitoSuyamaOP-104 15 TakayukiHiroseOP-105 CKDG3b-4 KenjiTamuraOP-106 AtsuhikoOchiOP-107 KoichiKido , ,,,OP-108 Nonagenarian903 TakehiroSejima

71

19

106

15 41914:3015:3015 OP-109 KodaiSatoOP-110 80 HirosiTanakaOP-111 ToshitakaShinOP-112 KeitaMinami008OP-113 80 GoKoboriOP-114 3-portLaparoscopicRadicalCystectomy(LRC) HidetoshiAkitaJA OP-115 AkihiroHayashida

16 41915:3016:3015 OP-116 TEPP)LRP HirokazuAbeOP-117 SyuntaroKohdaOP-118 HideoIwamotoOP-119

1 HideroMinamiOP-120

TakehisaOnishiOP-121 HiroakiKawanishiOP-122 ToshiakiShinojimaOP-123 OABTUR-P MunekadoKojima

17 41916:3017:3015 OP-124 TakaharuIchikawaOP-125 AkioHoshi

72

19


OP-126 TakeshiShichijoOP-127 HideoYukiOP-128 CK RurikoTakinamiOP-129 2case2 TakashiArai

1 41916:3017:301 PP1-001 KoichiOkadaPP1-002 YutakaSugiyamaPP1-003 TomomiNakagawaPP1-004 CytoreductiveNephrectomy

HironoriFukudaPP1-005 RCCCytoreductiveNephrectomy,Pre-SurgicalTargetedTherapy gakutamakiPP1-006 KenjiYoshidaPP1-007 ReiOnishiPP1-008 SuguruIkeshiroPP1-009 TakashiDejimaPP1-010 YukiNakamura

2 41916:3017:301 PP1-011 ClinicalT1pT3aupgrade MasayaMurakamiPP1-012 pT3aN0M0 MotohikoSugiPP1-013 JunNagayamaPP1-014 DaishiIchiokaPP1-015 TomohikoHara

73

19

106

PP1-016 TatsushiKawadaPP1-017 HidetoOtaPP1-018 3 TetsuyaImamuraPP1-019 10 YurikoKawataPP1-020 TeruhideWatanabe

3 41916:3017:301 PP1-021 GGCT- SusumuKageyamaPP1-022 O-glycanCTL MihokoYoneyama, PP1-023 YoshinosukeAmemotoPP1-024 GSK-3 HirooKurokiPP1-025 RASSalirasibHRAS SatoshiSugitaPP1-026 BBNDNACyp2a22 KazuhiroKanemotoPP1-027 KeitaroIida PP1-028 GemcitabineATRAZD6738 MakotoIsonoPP1-029 BCG RyosukeMuraiPP1-030 TakashiKawahara

4 41916:3017:301 PP1-031

MasashiMatsushima, PP1-032 RyuMuraokaPP1-033 varianthistology MakotoKagawaPP1-034 6 AkiraHoriuchi

74

19


PP1-035 cT3N2M0ypTaN0M01

SojunKanamaruPP1-036 SanoTomoyasuPP1-037 1(GC) SatoshiTakaiPP1-038 KiyoakiNishiharaPP1-039 GC3 YuminaMuto

5 41916:3017:301 PP1-040 lowrisk KazuhiroArakiPP1-041 YoichiroKatoPP1-042 YushiYamauchiPP1-043 TURBT/ KazuyukiYuge, PP1-044 BCGrelapsing MizukiKinoshitaPP1-045 -globulin MasashiArai, PP1-046 AtsushiIkedaPP1-047 Epiplakin KoheiMochizuki, PP1-048 CD155 MasahiroHagiwara, PP1-049 M2C

YosukeYasuda

6 41916:3017:301 PP1-050 YoshihisaKawaiPP1-051 KazuhikoOrikasaPP1-052 80 KazuyaSekiymama

75

19

106

PP1-053 DaiKouguchiPP1-054 MRI:inchwormsign KoheiChinoPP1-055 KazumasaSakamoto PP1-056 neutrophil-to-lymphocyteratio(NLR) KeiyuMatsumotoPP1-057 SatoruShimochiPP1-058

MasakiMomotaPP1-059 AyumuKusaka

7 41916:3017:301 PP1-060 PSA KojiNishizawaPP1-061 2394 SoUshijimaPP1-062 5~

YoshimasaKondoPP1-063 PSA NarushiYokota PP1-064 free/totalPSA KazufumiNakashima PP1-065 ShotaroYasuokaPP1-066 KousukeMikami PP1-067 MRI

ToshikazuTakedaPP1-068 RyosukeAndo

8 41916:3017:301 PP1-069 MRIPI-RADSversion2 TakeshiHanasakiPP1-070 MRIPI-RADSversion2T2 Seikokanzaki

76

19


PP1-071 PI-RADSv2MRI YutaTakeshimaPP1-072 Multi-parametricMRIPIRADSv2 KazushigeSakaguchiPP1-073 PI-RADSversion2MRI MichinobuOzawaPP1-074 MRI PI-RADScategory3 HirohitoNaitoPP1-075 MRI SuguruItoPP1-076 multi-parametricMRI

TakashiKurauchiPP1-077 MRI(PhilipsIngenia3.0T) TetsuoFukudaPP1-078 MRI DaigoOkada

9 41916:3017:301 PP1-079 24 GakuKurokawaPP1-080 13 AyatoOgataPP1-081 CTIBL(cancertreatmentinducedboneloss)

TomoyukiOidaPP1-082 YukiTakaiPP1-083 TomohiroShiraishiPP1-084 LHRH80

NobuyukiNishikawaPP1-085 ProGRPPSA MasahiroYashiPP1-086

HikaruMikamiPP1-087 YoshiakiKawamuraPP1-088 JunAkatsuka

77

19

106

10 41916:3017:301 PP1-089 AkihisaYaoPP1-090 KazunariTsuchihashiPP1-091 ShotaKawanoPP1-092 TakayukiHosoiPP1-093 T1b12Trifecta

KotaroOtsukaPP1-094 Trifecta DaisukeMotoyamaPP1-095 RAPNLPN AzumiArakiPP1-096 SatoruKiraPP1-097 ShoheiFujikawaPP1-098 AkiraJoraku

11 41916:3017:301 PP1-099 YasuhikoHiroseJAPP1-100 HiroshiKanoPP1-101 SatoshiFukataPP1-102 RyujiMatsumotoPP1-103 HiroyukiInabaJRPP1-104 MasafumiKitaPP1-105 5 YukiKobariPP1-106 MasatoshiTanakaPP1-107 KengoKawase

78

19


PP1-108 1 RyuheiKanaokaJA

12 41916:3017:301 PP1-109 NaokiTeradaPP1-110 NagahideMatsumuraPP1-111 JunWatanabePP1-112 D NaoyaFujikawaPP1-113 NorioKawasePP1-114 Ken-ichiTabataPP1-115 LRPRARP

PSMratelearningcurve IsseiSuzukiPP1-116 (LRP)(RALP)

YasukiyoMuraakmiPP1-117 RARP NobuhiroTakahashiPP1-118 KotaSugiura

13 41916:3017:301 PP1-119 KenjiMastudaPP1-120 TomoShimizuPP1-121 MitsuyukiKoizumiPP1-122 NamikoUemaPP1-123

TomihikoYasufukuPP1-124 YuichiUemuraPP1-125 AkihiroMaeda

79

19

106

PP1-126 CT YusukeUchidaPP1-127 3 KojiTamuraPP1-128 RyotaMaeyama

14 41916:3017:301 PP1-129 TUL NakamuraKeisukePP1-130 TUL NaokiNagasakaPP1-131 TUL TaishiroSasaharaPP1-132 YosukeFukiishiPP1-133 TUL AkiNishinoPP1-134 TUL MasashiImanoPP1-135 2cmf-TUL YutoBabaPP1-136 1f-TUL KimitsuguUsui

15 41916:3017:301 PP1-137 PNLTAPTUL-assistedPNL KentaroNagao, PP1-138 TUL-assistedPNL(TAP) TakashiDeguchiPLPP1-139 miniTAPTUL-assistedPNL MasayasuSugiyamaPP1-140 TUL-assistedPNL(TAP)67 SatoshiImaiPP1-141 TULPNL KokiTominagaPP1-142 PNL KatsukiMiuraPP1-143 TakuyaHamaguchiPP1-144 ECIRSendoscopiccombinedintrarenalsurgery YasuhiroFujii

80

19


PP1-145 ECIRS KenjiYamadaPP1-146 standardECIRSminiECIRS TadashiTabei

16 41916:3017:302 PP1-147 class TakamasaHoriuchiPP1-148 KentoMorozumiPP1-149 KatsukiInouePP1-150 MRI TakahikoSomaPP1-151 GIST MasahiroFujikawaPP1-152 1 AkiraHanashi PP1-153 TanseiSanjo, PP1-154 GC TakanoriMatsubaraPP1-155 Neuroendocrinecarcinoma YuyaIwamotoPP1-156 PD-L1,CTLA4 SahokoNinomiya

17 41916:3017:302 PP1-157 G8 ChiharuOnodaPP1-158 KatsukiTsuchiyamaPP1-159 DaisukeSetoPP1-160 SotaroKitaokaPP1-161 AokiYujiroPP1-162 (PSA)

MakotoMitsuhashiPP1-163 IgG41 RyoAmakawa

81

19

106

PP1-164 IgG41 HisajiKumagaePP1-165 IgG4 YuusukeYoneokaNTT

18 41916:3017:302 PP1-166 HiroshiYaegashiPP1-167 Pazopanib TakashiIshidaPP1-168 pazopanib KeisukeDoiPP1-169 ShoheiNakanoPP1-170 YasuhiroTerashimaPP1-171 Pazopanib MasaakiItoPP1-172 1stline GoTanigawaPP1-173 ShintaSuenagaPP1-174 YuSuzuki

19 41916:3017:302 PP1-176 1 KeiichiItoPP1-177 (TKI) MakiFujiwaraPP1-178 ToruInouePP1-179 HiroyukiMomozonoPP1-180 TetsuoFujitaPP1-181 TangoMochizukiPP1-182 YojiMurakamiPP1-183 PresurgicaltherapyTyrosineKinaseInhibitors(TKIs) MarikoSakamoto

82

19


PP1-184 YukiKatoPP1-185 1 KuniyasuMuraoka

20 41916:3017:302 PP1-186 SatoshiYamamotoPP1-187 50 ToruOnitaPP1-188 NatsuhoHayashiPP1-189 ShuheiYamadaPP1-190 Sugarbaker HirataKeitaPP1-191 KazutakaMaruoPP1-192 MasuoYamashitaPP1-193 12 MichioKosugiPP1-194 KoheiTakei

21 41916:3017:302 PP1-195 1cm KotaroSuzukiPP1-196 square(TURBO TaikiKamijimaPP1-197 (TURBO) YuhkiNakamuraPP1-198 (TURBO)

TURBO TakashiSeoPP1-199 TURBO YoshihoMiyatomiPP1-200 YuzoInabaPP1-201 BladderCancerIndexBCIPilotStudy TakahiroOsawaPP1-202 KanakoOhori

83

19

106

PP1-203 TURBT YushiHayashida

22 41916:3017:302 PP1-204 HideoShinsakaPP1-205 KoichiAikawaPP1-206 PSA ShunsukeMiyamotoJAPP1-207 PSASalvageRadiotherapy KeijiOgura, PP1-208 PSA MakotoAndoPP1-209 N1M0 MasatoMatsuzakiPP1-210 KazunobuKattoPP1-211 SatoshiTakadaPP1-212 TakafumiMinami

23 41916:3017:302 PP1-213 HiroshiMatsui , PP1-214 PSA HiroSatoPP1-215 Trimodalitytherapy GakuAraiPP1-216 IMRT DaikiKatoPP1-217 KenKuwaharaNTTPP1-218 YoshihiroTatsumiPP1-219 (IMRT) KaoriEndoPP1-220 Tomotherapy HiromiSatoPP1-221 IMRT KazutoshiOkubo

84

19


PP1-222 AtsushiTomioka

24 41916:3017:302 PP1-223 HirokiIchikawaPP1-224 YasuharuNagaiPP1-225 D-dimer AkitoKuromotoPP1-226 TakamichiMoriPP1-227 PSA YukiEndoPP1-228 5PSA TatsuakiOnukiPP1-229 ToshiyukiNakamuraPP1-230 highrisk/veryhighrisk TaisukeSuyamaPP1-231 pN1 IkuNinomiyaPP1-232

TeppeiMatsumoto

25 41916:3017:302 PP1-233 HideyukiFukuiPP1-234 MasashiOaePP1-235 D MasakiYoshidaPP1-236 4 TakakiTanakaPP1-237 14 MasahiroIinumaPP1-238 28 HiroakiKobayashiPP1-239 HirokiKatsumataPP1-240 SatoruTanifuji

85

19

106

PP1-241 TakahiroHirayama

89

20

106

2 42013:3014:001 SL2 iPS JunyaToguchida iPS

4 42014:0014:301 NaokiYoshimuraUniversityofPittsburgh,USASEL4 BladderPainSyndrome:Whyhasitbeensodifficulttoapprovenewtherapies? Philip Mark HannoStanford University School of Medicine, USA

5 42014:3015:001 ,SEL5 Prostatecancercanwepreventit? Fritz H. SchrderErasmus University Medical Center, The Netherlands

AI Symposium 42011:0512:051 (AI) AI-1 JunichiTsujii AI-2 AI YasushiOkuno AI-3 ArtificalIntelligence TakeshiOhdaira

ACU Lecture 42013:1513:301 ACU One-stageHypospadiasRepair:FutureisAsiatheEast TomohikoKoyanagi,

EAU Lecture 1 4209:059:251 AllenChiuMedicalSchoolofNationalYang-MingUniversity,TaiwanEAU1 Managementofthefailedhypospadiacurethra Christopher Chapple Sheffield Teaching Hospitals NHS Foundation Trust / Honorary Professor, University of Sheffield /

Sheffield Hallam University / Secretary General, European Association of Urology, UK

EAU Lecture 2 42015:0015:201 EAU2 Weneedtodonephronsparingsurgerywheneverpossible Hendrik Van PoppelUniversity Hospital KU Leuvan, Belgium

Message from Asia 4 42016:30~17:301 The blue print of next-generation robot surgical systems GyungTakMarioSungDong-AUniversityHospital,KoreaMFA4-1 NewRoboticPlatformsonHorizon2018 Koon Ho Rha Yonsei University, KoreaMFA4-2 Robotsurgicalsystemusingpneumaticactuators KenjiKawashima MFA4-3 TheConceptofRoboticAssistedSurgeryfromMedicaroidwithintheNDA RaizoYamaguchi

90

20


MFA4-4 MinimalAccessRoboticsUsingthedaVinciSinglePortPlatform James Porter Swedish Medical Center, USA

Discover Tomorrow 2 4208:00~9:001 Treatment of CRPC: un update and future perspectives Yeong-ShiauPuNationalTaiwanUniversityHospital,TaiwanDT2-1 Theroleofoxidativestressincastration-resistantprostatecancer,anditsdiagnosticand

therapeuticimplications MasakiShiotaDT2-2 Evolvingthetreatmentlandscapeforadvancedprostatecancer Robert H Getzenberg Veru Inc., USADT2-3 Expressionofandrogenreceptor,itsvariantandglucocorticoidreceptorinprostatictissueof

castrationresistantprostatecancerpatients Hanjong Ahn Asan Medical Center, University of Ulsan College of Medicine, Korea

Discover Tomorrow 3 4209:30~10:301 Discovering and targeting driver pathways in urogenital cancer JacobSeeTongPangChangGungMemorialHospitalLinkou,TaiwanDT3-1 RenallCellCancer William Kaelin Dana-Farber Cancer Institute and Harvard Medical School, USADT3-2 Roleofandrogenreceptorinluminalepithelialprogenitors Michael M. Shen Genetics & Development, Urology and Systems Biology at Columbia University Medical Center, USADT3-3 Discoveringandtargetingdriverpathwaysinurothelialcarcinoma TakashiKobayashi

2 42015:4516:452 EP2-1 WHO ShojirohMorinaga EP2-2 HiroshiMiyamoto EP2-3 WHO TakeshiKishida

3 42014:3015:303 Tips and Tricks / up-to-date EP3-1 RAPNhighcomplexitytumor TakeshiYamasakiEP3-2 ShujiIsotaniEP3-3 ToshinariYamasaki

4 42016:4517:453 EP4-1 TakamitsuInoue

91

20

106

EP4-2 ShoichiroMukaiEP4-3 KentoKanao

5 42014:3015:308 EP5-1 CKD-MBD TakashiShigematu EP5-2 KazuhikoTsuruya EP5-3 TadashiTomo

11 42015:2016:201 MRI / US fusion biopsy SY11-1 MRI- KazutakaSaitoSY11-2 MRIAI ToshitakaShinSY11-3 mpMRIbiopsies:cognitive,fusionandin-bore Rajeev KumarAll India Institute of Medical Sciences, India

12 42014:3015:302 SY12-1 LUTS? YoshihisaMatsukawaSY12-2 KoheiHashimotoSY12-3 ShingoHatakeyamaSY12-4 SeiNaito

13 42016:4517:452 SY13-1 YosukeYasudaSY13-2 TakashiKoyama SY13-3 ToshioTakagiSY13-4 CT AkiraNagahara

92

20


14 42014:3015:305

SY14-1 RihitoAizawa SY14-2 HiromichiIshiyama SY14-3 (HDR) YasuoYoshioka SY14-4 J-CROSstudy TakumaNomiya

15 42015:3016:308 pitfall SY15-1 3 ToruKannoSY15-2 pitfall

TakuyaKoieSY15-3 YasuyukiKobayashi

16 42016:3017:308 SY16-1 YoshifumiSugitaSY16-2 AkihiroKanematsuSY16-3 HideoNakai

JUA / AUA Joint Symposium 4208:009:308 ChairpersonsJohnDenstedtWesternUniversity,CanadaMasatoshiEtoKyushuUniversity,JapanJUA/AUA-1 Japanesetopicsforstonemanagement-epidemiology,endoscopicsurgery,andprevention Takahiro YasuiNagoya City University, JapanJUA/AUA-2 Cytoreductivesurgeryinpatientswithmetastaticrenalcellcarcinoma Tomoya FukawaTokushima University, Japan

93

20

106

JUA/AUA-3 Transperinealapproachforanofficebasedprostatebiopsy John WeiUniversity of Michigan Medical School, USA Panel Discussion (Prostate cancer)Moderators: Norio NonomuraOsaka University, Japan

J. Brantley ThrasherUniversity of Kansas Health System, USA Panelists: Seiji AraiGunma University, Japan

Kohei HashimotoSapporo Medical University, Japan Masaki ShiotaKyushu University, Japan

AUA Postgraduate Lecture 4209:3010:008 AUAP-1 Cardiovascularimplicationsofkidneystonedisease Ryan HsiVanderbilt University School of Medicine, USAAUAP-2 Tlr4dependentIL-6signalingaltersuropathogenfitnessthroughinhibitionofintracellularbacterial

communityformation Christina Ching Nationwide Childrens Hospital, Research Institute at Nationwide Childrens Hospital, Center for Clinical

and Translational Research, USA

JUA / EAU Joint Symposium 42010:0011:308Chairpersons:ChristopherChappleSheffieldTeachingHospitalsNHSFoundationTrust/HonoraryProfessor,UniversityofSheffield/

SheffieldHallamUniversity/SecretaryGeneral,EuropeanAssociationofUrology,UK

HideyasuMatsuyamaYamaguchiUniversity,JapanJUA/EAU-1 Malestressurinaryincontinenceafterradicalprostatectomy:Riskfactorsandurethralfunction Naoki KawamoritaTohoku University, JapanJUA/EAU-2 Robot-assistedpartialnephrectomyinJapan Nobuyuki HinataKobe University, JapanJUA/EAU-3 IssurgeryistheoptimalinitialtreatmentforHighRiskProstateCancer? Hendrik Van PoppelUniversity Hospitals KU Leuven, Belgium Panel Discussion (UC)Moderators: Yasutomo NasuOkayama University, Japan

Hendrik Van PoppelUniversity Hospitals KU Leuven, Belgium Panelists: Shingo HatakeyamaHirosaki University, Japan

Naokazu IbukiOsaka Medical College, Japan Hayato TakedaJapanese Foundation for Cancer Research, Japan

Debate 2 42015:3016:303 T1 DB2-1 T1b TsunenoriKondoDB2-2 T1b KatsunoriTatsugamiDB2-3 T1b MasanobuShigetaDB2-4 T1b MasahiroNozawa

94

20


Debate 3 42015:3016:305 DB3-1 TaroIguchiDB3-2 ShuzoHamamotoDB3-3 NaokiShiga

Debate 4 42016:3017:305 DB4-1 TohruNakagawaDB4-2 MotohideUemura DB4-3 BCG TakashiKobayashi

42010:0011:307 2017 ChieMatsushita YoshikoMaeda KeikoTakekawa

4208:009:0013 304 TadanoriSaitoh

JUA/UAA Oral 5 4208:009:002 Stone surgeries StephenLimMtElizabethMedicalCentre,SingaporeSoodongKimDong-A

MedicalCentre,SouthKorea

IS-33 Riskfactorsforperioperativecomplicationsinureteroscopy Yasuhiro NomaDepartment of Surgery, Juntendo University, Tokyo, JapanIS-34 Comparisonamongregionalanesthesiaandgeneralanesthesiainureteroscopiclithotripsy:A

national-basedstudy Min Hsin Yang Chung-Shan Medical University Hospital, Taichung, Taiwan ,Institute of medicine, Chung-Shan Medical

University, Taiwan

IS-36 Minipercutaneousnephrolithotomyforrenalstoneslargethan2.5cm:experienceinKaohsiungVeteransGeneralHospital

Chieh-Wen ChinDepart of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

95

20

106

IS-37 MiniPCNLversusstandardPCNL-aretrospectivecomparativeanalysisof372casesincalculilargerthan2cm

Anil Kumar SanwalSanwal Hospital, Jhansi, indiaIS-38 Roleoflaparoscopicureterolithotomyintheeraofendourologyanditssignificanceinadeveloping

country Sanjay ChaubeSt.Jude's Hospital, Department of Surgery, M.L.B. Medical College, Jhansi, IndiaIS-39 Translaparoscopicendourologicalapproach-Asafeandeffectiveapproachtostonemanagement Rishikesh PandyaNMC Specialty Hospital, Abu Dhabi, UAEIS-40 Theimpactofserumandurineosteopontinonurolithiasis Noriko TokuiHirosaki University Graduate School of Medicine, Hirosaki, Japan

JUA/UAA Oral 6 4209:0010:002 Infertility, andrology, sexual dysfunction TieZhouShanghaiChanghaiHospital,ChinaDavidColinWinkleMater

HospitalsComplex,Australia

IS-41 IndocyanineGreenangiographyassistedmicrosurgialsubinguinalvaricocelectomy:seeingisbelieving

Li Hsien TsaiChina Medical University Hospital, Taichung, TaiwanIS-42 AssociationBetweenInflammatoryBowelDiseaseandErectileDysfunction:ANationwide

Population-BasedStudy Meng Han ChouDepartment of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanIS-43 Impactsofmorningerectionsonself-confidenceandenergythroughtadalafilonce-a-dayand

androgenreplacementtherapyinmiddleagemen Yoshikazu SatoSanjukai Hospital, Sapporo, JapanIS-45 SexualfunctionandQualityoflifeinadultsurvivorsofchildhoodcancersinanAsianpopulation Chi-Fai NgSH Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Shatin, Hong KongIS-46 Low-intensityextracorporealshockwavetherapyinthetreatmentoferectiledysfunction-the

functionofcavernosalarterychangeaftertreatment Lin YangThe First Affiliated Hospital of Xian Jiaotong University, West Yanta Road, ChinaIS-47 TheEfficacyofaSexualHealthEducationInterventionforMaleRectalCancerPatients Kazuhito MatsushitaSt. Luke's International Hospital, Tokyo, JapanIS-48 UsefulnessofRigiScanEvaluationofNocturnalPenileTumescence Koichi NagaoToho University, Tokyo, Japan

JUA/UAA Oral 7 42010:0011:002 Adrenal, ureter, testis, penis, novel technology, others IS-50 Implantationofbio-fabricatedautologousadipose-derivedcellstructureintocryo-injuredurethraof

rabbits Sudha Silwal GautamShinshu University, Matsumoto, JapanIS-52 Endoureterotomyforureteralstricture:aretrospectivestudyofholmiumversus thuliumlasers Meng Han Chou Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan,

R.O.C., Taiwan

IS-53 RetroperitonealLymphnodeDissectionOutcomesinNewSouthWales Alfin Taddeo OkulloDepartment of Surgery, Westmead Hospital, Sydney, AustraliaIS-54 Useofilluminateduretericcatheterinretroperitonealsurgeryforurolithiasis-Ainnovativeway Sanjay ChaubeSt. Jude's Hospital, Department of Surgery, M.L.B. Medical College, Jhansi, India

96

20


IS-56 Advantageofurologicalexperiencewithbothtransperitonealandretroperitoneallaparoscopyinlymphnodebiopsyformalignantlymphomadiagnosis

Hajime TakamoriTenri Hospital, Nara, Japan

JUA/UAA Oral 8 42011:0012:002 Kidney transplantation, trauma & emergencies, urethroplasty & genital reconstruction and

pediatric urology MkYiuDepartmentofSurgery,UniversityofHongKong

AneeshSrivastavaRajivGandhiCancerInstituteandResearchCenter,IndiaIS-57 Renalfunctionchangeafterlivingdonornephrectomy:ChinaMedicalUniversityHospital

experience Po-Jen HsiaoChina Medical University Hospital, Taichung, TaiwanIS-58 Septicemiaandgraftfailureinkidneytransplantation:anobservationofnationwideinpatient

sample,during2005to2014 Syuan-Hao SyuWan Fang Hospital, Taipei Medical University, Taipei, TaiwanIS-59 Roleofrobotinrenaltransplantation:Asinglecentreexperienceandpointoftechnique: Mohankumar VijayakumarMuljibhai Patel Urological Hospital, Nadiad, Gujarat, IndiaIS-60 Inguinal/subinguinalartery/lymphaticsparingvaricocelectomywithopticalmagnificationin

childrenandadolescents:systematicreviewandmetanalysis Maurizio Pacilli Department of Paediatric Surgery and Department of Paediatrics, School of Clinical Sciences at Monash

Health, Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

IS-61 Systematicreviewoftheinfluenceofpenectomyonsurvivalrateofpatientswithpenilecalciphylaxis

Chang Tsung-Hsin Mackay Memorial Hospital, Taipei, Taiwan, Mackay Medical College, Taipei, TaiwanIS-62 GonadalfunctionandgonadalhistologyinpatientsraisedasmalewithDisorderofsex

development(DSD):longitudinalstudies Satoko MatsuyamaWomen's and Children's Hospital, Osaka, JapanIS-63 Relationshipsofoperationaldifficultiesandpostoperativeresultsinunilateralorchidopexy:

comparisonbetweenlessandMorethan1yearold Chihiro HayashiKanagawa Children's Medical Center, Yokohama, JapanIS-64 Therapeuticeffectsoftransurethralincisionforchildrenwithvoidingdysfunctionandobstruction

oflowerurinarytract Akiyoshi OsakaSaitama Medical Center Dokkyo Medical University, Koshigaya, Japan

JUA/UAA Oral 9 42013:3014:309 Renal tumors ThomasY.HsuehTaipeiCityHospitalRenaiBranch,TaiwanIS-66 ClinicalimpactofgeneticpolymorphismsofvascularendothelialrelatedinJapanesemetastatic

renalcellcarcinomapatientstreatedwithaxitinib Kazuyuki NumakuraAkita University Graduate School of Medicne, Akita, JapanIS-67 Mappingonthree-dimensionalphysicalmodels:anewmethodforplanningandnavigating

laparoscopicpartialnephrectomyinpatientswithendophyticrenaltumors Xie YuThe Affiliated Cancer Hospital of Xiangya, Central South University, Changsha, ChinaIS-68 Gaslesslaparoendoscopicsingle-portclamplesssuturelesspartialnephrectomy:Perioperative

outcomes Yosuke YasudaTokyo Medical and Dental University, Tokyo, Japan

97

20

106

IS-70 FDGPET/CTafterfirstmoleculartargetedtherapypredictssurvivalofpatientswithrenalcellcarcinoma

Noboru NakaigawaYokohama City University Graduate School of Medicine, Yokohama, JapanIS-71 Predictivefactorsforimmediateprogressionafternivolumabtherapyformetastaticrenalcell

carcinoma Tsunenori KondoTokyo Women's Medical University Medical Center East, Tokyo, JapanIS-72 NurseLedRenalCancerFollowUpProgramintertiaryTeachingHospitalSingleCentre

Experience Haider Khan BangashFIona Stanley Hospital, Perth, Australia

JUA/UAA Oral 10 42014:3015:309 Urothelial tumors, bladder SongWuTheThirdAffiliatedHospital,ShenzhenUniversity,ChinaJoelAldana

UniversityofthePhilippines,PhilippineGeneralHospital,Philippines

IS-73 ComparisonofDifferentTreatmentSchedulesofMitomycinCIntravesicalInstillationinHigh-RiskSuperficialBladderCancerPatients

Hong-Ray Chen Departments of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China

IS-74 BCGSubstrainofTiceIntravesicalInstillationTherapymightbeComparablewithConnaughtinTreatingNon-muscleInvasiveBladderCancer:ashorttermanalysis

Yu-Kuang ChenTaipei Veterans General Hospital, Taipei, TaiwanIS-75 Predictivesignificanceofabsenceofinchwormsignondiffusion-weightedMRIforprogressionof

thepT1bladdercancer Shugo YajimaTokyo Medical and Dental University, Tokyo, JapanIS-76 Clinicalpredictorsforhigh-gradepapillarybladdertumorbeforefirst-timetransurethralresection:

ConstructionandExternalValidationofaNomogram Ken WakaiToho University Sakura Hospital, Sakura, JapanIS-77 Subtypeclassificationbyurothelialdifferentiationmarkersstratifiedprognosisinpatientswith

muscleinvasivebladdercancer Tetsutaro HayashiUniversity of Hiroshima, Hiroshima, JapanIS-78 Asingle-centreexperienceofrobotic-assistedradicalcystectomywithurinarydiversion:

perioperativemanagement,operativetechniqueandoncologicaloutcomes Su-Wei HuTaipei Medical University-Shuang Ho Hospital, New Taipei City, TaiwanIS-79 Coexistenceofpreoperativeanemiawithhydronephrosissignificantlyincreasedtheriskof

extraurothelialrecurrenceandlymphnodemetastases Ryo YamashitaShizuoka Cancer Center, Shizuoka, JapanIS-80 Prognosticindicatorsofmortalityandmorbidityfollowingradicalcystectomyforcarcinomaof

bladder:12-yearexperiencefromatertiarycentreinHongKong Ach TamDepartment of Surgery, Queen Mary Hospital, Pokfulam, Hong Kong SAR

JUA/UAA Oral 11 42015:3016:309 Infection and stone PremGyawaliTribhuvanUniversityTeachingHospital,NepalIS-81 clinicalimplicationSbetweenstoneBACTERIAcultureandpostoperativeCOMPLICATIONSfor

tubelesspercutaneousnephrolithotomy Hsiao Shu Chuan Department of surgery of Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, TaiwanIS-82 Riskfactorsassociatedwithfeverposttubelesspercutaneousnephrolithotomy Chao-Yuan ChangFar Eastern Memorial Hospital, Shulin, Taiwan

98

20


IS-83 TreatmentTimingandUrinaryDrainageInfluenceonOutcomeofUrinaryTuberculosis Tsu-Feng LinMackay Memorial Hospital, Taipei, TaiwanIS-84 RiskfactorsforPseudomonas aeruginosa -causingurosepsis:Howdoesurologicalintervention

contributetolowermortalityrate? Katsumi Shigemura Kobe University Hospital, Kobe, Japan, Kobe University Graduate School of Health Science, Kobe,

Japan, Infection Control Team, Kobe University Hospital, Kobe , Japan

IS-85 Studyofneworalquinolones(levofloxacinandsitafloxacin)asprophylacticantimicrobialagentsintransrectalprostateneedlebiopsy

Hitoshi Oh-okaKobe Medical Center, Hyogo, JapanIS-87 Patternofurinarymetabolitesexcretioninpatientswhoreceivedbariatricsurgery Nicole Miu Yee Cheng Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong,

Shatin, Hong Kong, China

IS-88 G-protein-coupledestrogenreceptorreducestightjunctiondisruptionbycontrollingZO-1andoccludinexpressionviamiRNA/MMP2pathwaytopreventkidneystone

Li ZuoChangzhou No.2 People's Hospital of Nanjing Medical University, Jiangsu, China

JUA/UAA Oral 12 42016:3017:309 Female LUTS, IC, neuro-urology and incontinence Myung-SooChooAsanMedicalCenter,UniversityofUlsan,SouthKoreaIS-93 TheeffciencyandsafetyofTVTABBREVOversusTVTEXACTinthenormalweightand

overweightpatientsaffectedbystressurinaryincontinence Yi SunWest China Hospital of Sichuan University, Chengdu, ChinaIS-94 Theimpactofvesicourethralanastomosistechniqueonpostoperativeurinaryincontinenceafter

robot-assistedradicalprostatectomy Tsuyoshi MajimaNagoya University Graduate School of Medicine, Nagoya, JapanIS-95 ConcomitantonabotulinumtoxinAdetrusorandsphincterinjectioninpatientswithsuprasacral

spinalcordinjury Yu-Hui Huang Department of Physical Medicine and Rehabilitation, Chung Shan Medical University Hospital, Taichung,

Taiwan, Chung Shan medical University, Taichung, Taiwan

IS-96 TherapeuticEffectsofTRPV1TargetingGeneTherapyonBladderOveractivityandNociceptioninaRatModelofExperimentalColitis

Shun TakaiNagoya University Graduate School of Medicine, Nagoya, Japan

4 4208:009:003 VP-18 TomokazuKimuraVP-19 1 KeitaNakaneVP-20 YutakaTakezawaVP-21 HybridtargetingMRI-USfusion KazumiKamoiVP-22 KoichiNagaoVP-23 KoichiNagao

99

20

106

5 4209:0010:003 VP-24 HiroyukiTsunemoriVP-25 Highcomplexitytumor KosukeFukayaVP-26 robot-assistedlaparoscopicpartialnephrectomy

RAPN) NoriyukiItoVP-27 TakeshiYamasakiVP-28 MutsushiKawakitaVP-29 YuyaSoeda

6 42010:0011:003 VP-30 KazuhiroIshizakaVP-31 RARP KojiInoueVP-32 Veryhigh riskRARP KazushiHirakawaVP-33 (RAPN) FumiyaHongoVP-34 JunAjikiVP-35 RAPN KazuyaHanai

18 4208:009:005 OP-130 -223NaF-PET

TaroIguchiOP-131 -223 DaiWatanabeOP-132 -223Ra-223

3 GoKimuraOP-133 -223QOL MasakazuNakashimaOP-134 (Ra-223)DWIBS

TsuzumiKonishi

100

20


OP-135 2236 SohgoTsutsumi, OP-136 CRPC)223(223Ra)

MasahiroEmuraOP-137 Ra223 HitosiShimodate

19 4209:0010:005 OP-138 JunjiYoneseOP-139 StageD2highvolumedisease ToshihiroSaitoOP-140 T4 SatoruKawakamiOP-141 1

CHAARTEDcriteriaLATITUDEcriteriabonescanindex ShukoYoneyamaOP-142 NaokazuIbukiOP-143 CRPC HirokazuTakedaOP-144 Highvolume TakashiIkedaOP-145 MasahitoWatanabe

20 42010:0011:005 OP-146 CAB

TaroIguchiOP-147 CRP TeruoInamotoOP-148 C(CRP)

KazutakaSaitoOP-149 MasaakiImamuraOP-150 KazunoriHagaOP-151 TomoakiHakariya

101

20

106

OP-152 TetsuyaMiuraOP-153 TomohikoOguchi

21 42011:0012:005 OP-154 Gn-RH YumikoYokomizo, OP-156 TomonoriKatoOP-157 MasatoOkunoOP-158 androgendeprivationtherapyADT KatsuhiroItoOP-159 CRPC SatokoKojimaOP-160 LH-RH YoichiIwamotoOP-161 GnRHantagonistGnRHagonist JumpeiAsakawa

22 4208:009:006 OP-162 glucosetransporter(GLUT)sodium-dependentglucose

transporter(SGLT) MinoruKobayashiOP-163 MitsuoOkadaOP-164 RNARNA AtsushiOkato, OP-165 RNA(miR-10a-5p) TakayukiArai, OP-166 19972017 TakashiKarashimaOP-167 microRNA-451a YasutakaYamada, OP-168 Xp11.2TFE3 MasayaBabaOP-169 MicrofluidicdeviceCirculatingTumorCells JunIto

23 4209:0010:006 OP-170 CKD-CT- HiroshiHaradsa

102

20


OP-171 DWI MasahiroSumuraOP-172 ClearCellPapillaryRenalCellCarcinomaCT TaroBannoOP-173 sunitinib21RDI KanaIwamotoOP-174 (TKI) JunMoritaOP-175 IchiroChiharaOP-176 MioSamejimaOP-177 TKI2 NoboruShibasaki

24 42010:0011:006 OP-178 SatoshiTamadaOP-179 3 KeisukeTsujiOP-180 TakeshiChiyomaruOP-181 KazumaOguraOP-182 ShuyaKandoriOP-183 KeijiKatoOP-184 KenichiHaradaOP-185 TakeshiYuasa

25 42011:0012:006 OP-186 -CheckMate025- SuguruShirotakeOP-187 NaotakaNishiyamaOP-188 HidekazuTachibanaOP-189 YusukeSato

103

20

106

OP-190 (irAE) ChieHommaOP-191 NivolumabAxitinib SunaoShojiOP-192 3

MasayukiSano

26 42013:3014:306 OP-193 YoichiKakutaOP-194 2 YuichiHasegawaOP-195 AkihikoMitsukeOP-196 TadahikoTokumotoOP-197 KenMoritaOP-198 ToshihiroShimizuOP-199 HidetoshiIshigooka

27 42014:3015:306 OP-200 ReducedPort MasahiroNittaOP-201 2 KoichiTsutaharaOP-202 HiroakiNishimuraOP-203 TatsuoYonedaOP-204 modifiedDFPPIgG DaikiIwamiOP-205 RyoheiYamamotoOP-206 TomokazuShimizu

28 42015:3016:306 OP-207 ToshihiroAsai

104

20


OP-208 MamoruKusakaOP-209 RituximabABO JunjiUchidaOP-210 2017 JunSugimuraOP-211 aHUS2 NaokiMitsuhataOP-212 YukiNakagawa,OP-213 Pfannenstielreducedportsurgery YasuyukiAkitaOP-214 ShiroFujikata

29 42016:3017:306 OP-215 MasashiNakayamaOP-216 ShinsukeHayamiOP-217 MakotoKurosawaOP-218 FukujiKondoOP-220 MakotoIwasaki OP-221 G8 MutsushiYamasakiOP-222 TatsuhikoHoshii

30 42013:3014:307 OP-223 YuminaIwamuraOP-224 QOL TomoyukiMakinoOP-225 HDR

KazuhikoOshinomiOP-226 N1High-dose-ratebrachytherapy HideyasuTsumuraOP-227 1252 KotaroObayashi

105

20

106

OP-228 HisakazuOdakaOP-229 QOL FumisatoMaesakaOP-230 FocalTherapy YoshiakiWakumoto

31 42014:3015:307 OP-231 I-125PSA NoriakiSanto OP-232 IPSSresolution HidehisaMoriOP-233 I-125PSA YuOzawaOP-234 TsutomuYunoOP-235 TomoharuFukumoriOP-236 PSAnadirPSA ShujiKotohOP-237 I-125 KimioTakai

32 42015:3016:307 OP-238 FumioTsukudaOP-239 oligometastaticprostatecancer

ShojiKogaOP-240 80Gy HiroshiKakizakiOP-241 CTonrails(IGRTimage-guided

radiotherapy) HiromichiIwamuraOP-242 CyberKnife KosukeTakeharaOP-243 IMRT NaotoKaburakiOP-244 IMRT SuenagaTakehiroOP-245 NobuteruKubo

106

20


33 42016:3017:307 OP-246 HiromasaSakamotoOP-247 1 SatoruMaruyamaOP-248 SatoruMaruyamaOP-249

YukiKyodaOP-250 HidetoUekiOP-251 PSA0.2ng/ml

AkiraKazamaOP-252 Lymphnodesurvey KojiHatanoOP-253 QOL HidemasaKawamura,

34 42013:3014:3011 OP-254 MasanoriTabaraOP-255 () YasushiYumura ,

OP-256 2015() YasushiYumura ,

OP-257 HiroshiMasudaOP-258 Nagaosubinguinal HideyukiKobayashiOP-259 ShinImaiOP-260 TomokiTakedaOP-261 PSA KeiyuIsaji

107

20

106

35 42014:3015:3012 OP-262

TeruakiIwamotoOP-263 TESEAZFGENOSEARCHTM MasakazuOohashiOP-264 MitsuruKomeya, OP-266 middleage~

~ KimiyasuIshikawaOP-267 ShuheiIshiiOP-268

AkikoItogaOP-269 YasuyukiInoue

36 42015:3016:3013 OP-270 LOH JintetsuSohOP-271 FtM TakahiroKirisawaOP-272 SatoshiKitaharaOP-273 HypogonadismHypogonadism ShinichiroFukuharaOP-274 LOH IppeiHiramatsu, OP-275 YutakaHoriguchiOP-276 KoujiIzumi

37 42016:3017:3014 OP-277 ERAS:(QoR-40J) KenjiKawamuraOP-278 DPC KenjiKawamuraOP-279 MasakiHaraoka

108

20


OP-280 MasashiTakaiwaOP-281 KiyotoNagamoriOP-282 HiroshiYamadaOP-283 TakaakiTamuraOP-284 ShinjiUrakami

38 42013:3014:3015 OP-285 Whole-bodyMRI(WB-MRI) HiromichiIwamuraOP-286 Radium-223BONENAVI

SPECT(GI-BONE) KoichiUemura, OP-287 FRAXADT YujiHakozakiOP-288 ADTBPH HiroshiNagaeOP-289 ADT ShingoToyodaOP-290 (SRE) HisashiMatsushimaOP-291 Bonescanindex TaroMurataOP-292

SeiichiKato

39 42014:3015:3015 OP-293 PSA

AtsushiTakahashiOP-294 PSA ShinsukeHamadaOP-295 (RARP)1000PSA

TakeshiKashima, OP-296 MRI YusukeIemura

109

20

106

OP-297 PI-RADSv2ISUPprogression-freesurvival NobuyoshiTakeuchiOP-298 Gleasonscore89,10 KoichiMiyamaeOP-299 3+4=74

ShunSatoOP-300 ISUPPSA MasanoriHanamoto

40 42015:3016:3015 OP-301 ShuyaMatsubaraOP-302 60 YukiOkinakaOP-303 S2,3PSAF/TPSA TohruYoneyama,OP-304 PSA(PSA-Gi)F/TPSA TohruYoneyamaOP-305 PSAglycoisoform(PSA-Gi) TakahiroInoueOP-306 (AI)PSA SatoshiNittaOP-307 TakumiTakeuchiOP-308 MRI JunichiroIshioka

41 42016:3017:3015 OP-309

KeisukeHataOP-310 PSA TakeshiHashimotoOP-311 AkihiroGorikiOP-312 clinicalsignificantcancer MasatsuguMiyashitaOP-313 2017

ManabuKamiyamaOP-314 80 YasunoriAkashi

110

20


OP-315 AkinoriTakeiOP-316 ShinichiSakamoto

26 42015:3016:301 PP2-001 Carbonicanhydrase9 KengoHoriePP2-002 ()AZU1

MotohideUemuraPP2-003 RNA ToshiroKinouchiPP2-004 RCC-GP1 ShotaroNakanishiPP2-005 Artemisinin IkuoKobayashiPP2-006 GPI-80 TomoyukiKatoPP2-007 Stage1TM4SF1 TetsuyaShindoPP2-008 AnnexinA1 MarikoYamanoi,PP2-009 mTORC1 MasayukiKurokawaPP2-010 MakiYoshino

27 42015:3016:301 PP2-011 PD-L1sunitinib TakutoHaraPP2-012 miR-99a-3p YouichiOsakoPP2-013 Sunitinib JunItoPP2-014 microRNA-1274aBonemorphogeneticproteinreceptor

type1BBMPR1B TakashiSakaguchiPP2-015 miR-122occludin CongWangPP2-016 ExsomalmiR-224 NakanoriFujii

111

20

106

PP2-017 ritonavirixazomib TakakoAsanoPP2-018 GSK39-ING41 TsutomuAnrakuPP2-019 phenoxodiolAkt

MakotoIsonoPP2-020 NaokoArichi

28 42015:3016:301 PP2-021 EverolimusCompleteResponse TakahiroOgawaPP2-022 Nivolumab1 SuguruKadomotoPP2-023 MotohiroNakamuraPP2-024 NivolumabirAE AkitakaSuzukiPP2-025 SatoshiAndoPP2-026 HirokiTakamoriPP2-027 TakashiKatoPP2-028 SatoruYumibaPP2-029 TsubasaNenoiPP2-030 NLRPLRLMR DaikiIkarashi

29 42015:3016:301 PP2-031 Nivolumab HiroyukiNosePP2-032 Nivolumab MasashiOhshimaPP2-033 MototsuguMuramakiPP2-034 KojiHoshinoPP2-035 2 ShunIwasa

112

20


PP2-036 nivolumab ReonaNishimuraPP2-037 nivolumab tatsuyaotakiPP2-038 KenjiNakamuraPP2-039 DaichiKobayashiPP2-040 Nivolumab AtsushiKoizumi

30 42015:3016:301 PP2-041 ShimpeiSugiuraPP2-042 GoAnan, PP2-043 ShogoTakadaPP2-044 AkinoriMinatoPP2-045 pN KeitaroWatanabePP2-046 75 SoheiKandaPP2-047 MinamiOmuraPP2-048 GCCR MasayukiTakataPP2-049 Gemcitabine+Nedaplatin NobuhikoMizunoPP2-050 FuminoriSakurai

31 42015:3016:301 PP2-051 MomokoKatoPP2-052 ShuheiAoyamaPP2-053 8 YumikoOkunoPP2-054 HiroshiMasumoto

113

20

106

PP2-055 YasutoshiYoshiyamaPP2-056 YoichiMori, PP2-057 BCG() MariYamasakiPP2-058 BCG7 TaketoKawaiPP2-059 BCGBCG ToruYamadaPP2-060 TakumaSato

32 42015:3016:301 PP2-061 activesurveillance SoheiTakahataPP2-062 60-PRIAS-JAPANstudy- TakumaKatoPP2-063 -PRIAS-JAPAN- TakumaKatoPP2-064 AkiraHisakanePP2-065 LDR)

TsuyoshiMatsuiPP2-066 EPICSF-8QOLRARPvsbrachytherapyBT)vsactive

surveillanceAS ShuichiShimada PP2-067 PSA

YuyaYamadaPP2-068

DaisukeYamadaPP2-069 25PSA RyoOki

33 42015:3016:301 PP2-070 Ra-223 RikoNemotoPP2-071 Ra-223 YuichiKatsuoka

114

20


PP2-072 Ra-223 HideakiShimoyamaPP2-073 Radium-223 RikiyaMatsumotoPP2-074 Radium-223 YoshifumiHoriPP2-075 223

HirokazuIshidaPP2-076 223Ra NaotoTokuyamaPP2-077 -223 KunihisaNezuPP2-078 BONENAVI TakeshiUjike PP2-079 FDG-PET-MRI TokikoNiimura

34 42015:3016:301 PP2-080 Ra-223Bonesacanindex ToshitakaUematsuPP2-081 BONENAVI-223 YosukeShimizuPP2-082 223 TomohikoKamasakoPP2-083 Ra-223 YoichiroToyonagaPP2-084 -223 KotaUmedaPP2-085 Ra-223 YosukeShibataPP2-086 YoshiyukiOkadaPP2-087 Ra-223 YuuSakuradaPP2-088 -223 ManabuKamiyamaPP2-089 Radium-223 MasahiroYanagisawa

35 42015:3016:301 PP2-090 YoshihiroKamiyama,

115

20

106

PP2-091 YukakoMoriPP2-092 NBI NoriyukiKanemitsu, PP2-093 YuiMatsudaPP2-094 TakeshiOkinamiPP2-095 MamiKatoPP2-096 YokoAzekoshiPP2-097 YoheiSatakePP2-098 TakaakiIto

36 42015:3016:301 PP2-099 HirokiSuekanePP2-100 LUTSAGEs HayatoYamamotoPP2-101 MayuYagiPP2-102 HiroshiKiuchi PP2-103 YoshitakaAokiPP2-104 obstructivesleepapneasyndromeOSAS

YasuyukiMiyauchiPP2-105 KeisukeKibaPP2-106 HisaeNishiiPP2-107 NarumiTaniguchiPP2-108 ICIQ-SF(InternationalConsultationonIncontinenceQuestionnaire-ShortForm)

SatoshiHonda,

116

20


37 42015:3016:301 PP2-109 RyoIguchiPP2-110 HiroshiMaedaPP2-111 YusukeShiraishiPP2-112 RyoMaruyamaPP2-113 PfannenstielReducedPort TakeoNomuraPP2-114 cmcm HirotakaMatsuiPP2-115 NobuhisaHagiwaraPP2-116 Grynfelt-Lesshafthernia RyoTsukamotoPP2-117 1 MasastoYanagiPP2-118 3 AkinoriNukui

38 42015:3016:301 PP2-119 RARPsurgicalstepBMI MitsuguKanehiraPP2-120 TsutomuHamasakiPP2-121 RALP YotaNakajimaPP2-122 HiromuInaiPP2-124 KosukeSadahidePP2-125 YoshikiKurizakiPP2-126 MasanoriKonoPP2-127 RARP1 MotoakiHatoriPP2-128 TakaoMishima

117

20

106

39 42015:3016:301 PP2-129 RARP) KojiHarimotoPP2-130 ToshikiAoyagiPP2-131 gradingsystem MasashiNishinoPP2-132

ToshitakaUematsuPP2-133 RARP KazunoriIwasakiPP2-134 ToruKimuraPP2-135 MitsuhiroNaritaPP2-136 AtsushiYamauchiPP2-137 HiroshiMikamiPP2-138 RALP JunjiKitamura

40 42015:3016:301 PP2-139 pT3 BandoYukariPP2-140 RARP RyoInouePP2-141

HidetoshiTabataPP2-142

ShunsukeHoriPP2-143 TaichiKanzawaPP2-144 MototsuguMuramakiPP2-145 ShintaroNaritaPP2-146 RetziussparingRALP TohruMiyagi

118

20


PP2-147 TAR(TotalAnatomicalReconstruction)

RyosukeSuzukiPP2-148 RARP2 KenichiroSekii

41 42015:3016:302 PP2-149 KazuyoshiIijimaPP2-150 KotaIidaPP2-151 YukiKatsumataPP2-152 T1 RyuichiroArakakiPP2-153 NoriyukiMakitaPP2-154 XiRAPN1 JunjiIshizakiPP2-155 KazumasaMatsumotoPP2-156

TakeshiYoshikawaPP2-157 TakahitoEndoPP2-158 TakashiShimizu

42 42015:3016:302 PP2-159 HiroshiIwamuraPP2-160 KosukeNakanoPP2-161 MarikoTabataPP2-162 TakahiroOshinaPP2-163 SoichiroShimuraPP2-164 SatoshiHachisuka

119

20

106

PP2-165 RyouNakayamaPP2-166 1 KohkiDoiPP2-167 ToshimitsuMatsuokaPP2-168 6 TakumaOshiro

43 42015:3016:302 PP2-169 HideakiTakadaPP2-170 YumikoSaitoPP2-171 FDG-PET/CT SeijiAsaiPP2-172 YoshitakaItami, PP2-173 HirotakeKodamaPP2-174 DaisakuHiranoPP2-175 SatoshiIshitoyaPP2-176 KoichiNishimuraPP2-177 KazutakaFukuyama PP2-178 PD-1 NozomiHayakawa

44 42015:3016:302 PP2-179 PSA KeisukeKuriharaPP2-180 HidekiAdachiPP2-181 JunKasugaPP2-182 HisashiTakeuchiPP2-183 CRPC(ABI) ShinyaSomiya

120

20


PP2-184 TatsuyaUmemotoPP2-185 MasaruHasumiPP2-186 (CRPC)

ToshinoriNishikimiPP2-187 DaigoFunakoshiPP2-188 2 DaisukeYamashita

45 42015:3016:302 PP2-189 KazukiKitajimaPP2-190 IppeiKojimaPP2-191 TasukuHiroshigePP2-192 CRPC KyoheiYasunoPP2-193 ShinpeiSaitoPP2-194 PSAPSA-PFS ToshihideShishidoPP2-195 KiyoshiHashimotoPP2-196 1

TakeshiMitomi PP2-197 GnRHantagonist,AR,D2

HidekiMukouyamaPP2-198 ShigeruHosoki

46 42015:3016:302 PP2-199 ob/ob TakeshiSasaki, PP2-200

NaoyukiYamanaka

121

20

106

PP2-201 Galectin-3 KeiDaizumotoPP2-202 PSA YasuhiroShibataPP2-203 YusukeKisoPP2-205 ManabuUenoPP2-206 TatsuyaIharaPP2-207 RyoheiYoshinagaPP2-208 Airchargecatheter TsukasaMasuda

47 42015:3016:302 PP2-209 5 HiroshiMasudaPP2-210 1

TakahisaDomenPP2-211 1 TakashigeNamimaPP2-212 AtushiWanifuchiPP2-213 1 AkikoNakajima PP2-214 BPH DaisukeGotohPP2-215 (KYU-PROStudy) KeiichiroIzumiPP2-216 BPHLUTS NaokiHiraharaPP2-217 Holep

TakeshiInagakiPP2-218 HoLEP HideoSakamoto

48 42015:3016:302 PP2-219 YuzoNakano

122

20


PP2-220 MasashiNomiPP2-221 ESBL AkifumiYokooPP2-222 KazuakiYamanakaPP2-223 MasatoDobashiPP2-224 BunyaKawamotoPP2-225 3 NoboruNumaoPP2-226 2 SeiichiSaitoPP2-228 TetsushiSakamoto

49 42015:3016:302 PP2-229 KosukeShimizuPP2-230 KensukeHikamiPP2-231

AtsushiOnishiPP2-232 EijiMatsubaraPP2-233 TakumiEndoPP2-234 KyokoBabaPP2-235 KanaoKobayashiPP2-236 2017 NoriyasuUwatokoPP2-237 1 MasaharuNakaiPP2-238 KoichiroSuzuki

50 42015:3016:302 PP2-239 ToshikiAnami

123

20

106

PP2-240 YujiKusudaPP2-241 daVinciXi ShinyaOharaPP2-242 TetsuyaNakadaPP2-243 TetsuyaImaoPP2-244 YujiTokuda21PP2-245 RAPN YoshinoriOshiroPP2-246 RAPN HirotoKotakaPP2-247 KoheiEdamuraPP2-248 FumitoYamabe

127

21

106

42114:5015:201 PL OsamuOgawa

3 42113:1013:401 SL3 MitinoriSaitou JST ERATO

iPS

4 42114:0514:451 SL4 ShizukaIjuin

6 42111:3012:001 SEL6 Combinatorialandmulti-modaladvancesintreatmentofmetastaticprostatecancer Martin GleaveUniversity of British Columbia, Canada

7 42113:4014:001 RI SEL7 PSMA-ligands-impactinprostatecancerpatients Frederik L. GieselUniversity Hospital Heidelberg, Germany

Message from Asia 5 4218:30~9:301 New frontiers in robot-assisted urological surgery JamesPorterSwedishMedicalCenter,USAMFA5-1 ExperiencewithR-VEILinCarcinomaPenis Sudhir K Rawal Rajiv Gandhi Cancer Institute and Research Centre, IndiaMFA5-2 Theartofbalanceinprostatecancerdiagnosis.IsMRIfusionrobotassistedprostatebiopsythe

holygrail? Christopher WS Cheng Singapore General Hospital, SingaporeMFA5-3 Evolutionofrobotictechniquesexpandstheboundaryofapplicationonurologicsurgeries MutsushiKawakita

6 42116:3017:302 EP6-1 DNA ShusukeAkamatsuEP6-2 LiquidBiopsy MasayoshiNagataEP6-3 KosukeMizutaniEP6-4 liquidbiopsy TakatsuguOkegawa

128

21


7 4218:309:303 EP7-1 MitsuruYasudaEP7-2 RyoichiHamasuna EP7-3 ShinIto

8 42114:3015:304 ~ EP8 AtsushiIwasa

9 4218:309:3013 EP91 KentaroMizuno EP92 YasuyukiNaitohEP93 management KimihikoMoriya

Up-to-Date 2 4219:30~10:301 Topics in uroepithelium and bladder sensation Myung-SooChooAsanMedicalCenter,UniversityofUlsanCollegeofMedicine,KoreaUD2-1 UroepitheliuminBladderMechanosensoryTransductionandSignaling Sylvia O Suadicani Albert Einstein College of Medicine, USAUD2-2 Newunderstandinginurgency Stefan De Wachter University Hospital Antwerpen, University Antwerpen, BelgiumUD2-3 Pharmacologicalmodulationofbladdersensation YasuhikoIgawa

Up-to-Date 3 42110:30~11:301 Urinary biomarkers of bladder cancer: an update and future perspectives KesavanEsuvaranathanNationalUniversityofSingapore,SingaporeUD3-1 Anovel,robustmultiplexurine-basedimmunoassayforbladdercancerdetection Charles Joel Rosser University of Hawaii Cancer Center / University of Texas Southwest Medical Center, USAUD3-2 Cxbladder:ahighsensitivityurinetestforthesurveillanceofurothelialcarcinoma Parry Guilford University of Otago / Pacific Edge Ltd, New ZealandUD3-3 Urinarybiomarkersofbladdercancer Wun-Jae Kim Chungbuk National University, Korea

129

21

106

Up-to-Date 4 4218:30~9:304 CRPC: tumor heterogeneity and clinical diversity RobertHGetzenbergVeruInc.,USAMASalamFoundationofBangladesh,BangladeshUD4-1 TargetingDriverOncogenesinmCRPC:RecentAdvancesTowardsPrecisionOncology Martin Gleave University of British Columbia, CanadaUD4-2 Updatesonthemanagementofneuroendocrineprostatecancer Himisha Beltran Weill Cornell Medical College, USAUD4-3 NetworkMedicinetoOvercomeDrugResistanceinCRPCorNEPC:DrugEfficacy

Reprogramming TakeoKosaka

17 42116:3017:301 High risk SY17-1 Highrisk JunTeishimaSY17-2 Highrisk KazunoriHattoriSY17-3 High-riskneoadjuvant ShintaroNarita

18 42115:3016:302 SY18-1 JunichiMochidaSY18-2 NativeTissueRepair YasukuniYoshimuraSY18-3 LSC MasahiroNarushimaSY18-4 MasamiTakeyama

19 4219:3010:303 2018 Men's Health SY19-1 iPSLeydig TakakiIshida iPSSY19-2 SuguruKawato, SY19-3 EDED ShinyaFurukawa

130

21


20 42110:3011:303 SY20-1 KojiShiraishiSY20-2 HiroshiOkuno SY20-3 HiroshiOkada

21 42114:3015:303 salvage SY21-1 PSAVS AkiraYokomizoSY21-2 NobumichiTanakaSY21-3 HiroshiSasaki

22 42115:3016:303 AYA SY22-1 AYA MasakiMandai SY22-2 AYA TakahiroKojimaSY22-3 YasushiYumura

23 42116:3017:303 SY23-1 YusukeNakazawaSY23-2 iPS AtsushiOkadaSY23-3 ShinichiSakamoto

24 4219:3010:304

SY24-1 KeynoteLecture William KaelinDana-Farber Cancer Institute and Harvard Medical School, USASY24-2 EijiroNakamura

131

21

106

SY24-3 KeiichiKondo

25 42115:3016:304 SY25-1 KousukeWatanabeSY25-2 UtsunomiyaHiroko SY25-3 TakafumiTahata

26 42116:3017:304 SY26-1 ShinjiKageyama SY26-2 ShizukaIida SY26-3 MiyabiInoueSY26-4 6 YoichiroKajita

27 4219:3010:3013 SY27-1 - KojiMitsuzukaSY27-2 KojiOkiharaSY27-3 APCCC2017 HiroyoshiSuzuki

28 42110:3011:3013 SY28-1 Metabolicsyndrome YoshitakaAokiSY28-2 NeuralCross-talk TomonoriMinagawaSY28-3 Circadianrhythm HiromitsuNegoro

Debate 5 42115:3016:301 BCG refractory DB5-1 BCGrefractoryChangingconcept EijiKikuchi

132

21


DB5-2 BCGrefractoryBasis&Performance MakitoMiyakeDB5-3 BCGrefractoryTips&Tricks JunMiki

Late-breaking & Encore Session 42110:4511:452 Global trialsubLBS-1 Pembrolizumab(pembro)versuspaclitaxel,docetaxel,orvinflunineinrecurrent,advancedurothelial

cancer(UC):Long-termresultsfromthephase3KEYNOTE-045trialwithJapanesesubgroupanalysis HiroyukiNishiyama LBS-2 LATITUDE NobuakiMatsubara LBS-3 (NIVO)(EVE)

:CheckMate0253 SatoshiFukasawa , CheckMate 025 study group

4219:3010:3012

42 4218:309:305 OP-317 SatoshiYamaguchiOP-318 SayaKurataOP-319 HideoOtsukiOP-320 MakotoTaguchiOP-321 ShingoMyoenOP-322 SOFAqSOFA HiroshiFukushimaOP-323 KeisukeIshikawaOP-324 KentaroImaizumizumi

43 4219:3010:305 OP-325 TUL ManabuSakaki

133

21

106

OP-326 CT3D-MSDTUL YuyaIwahashiOP-327 10mmf-TUL MayukoKatoOP-328 DustingTUL YujiKatoOP-329 MasakiWatanabeOP-330 Validationstudy TakaakiInoueOP-331 fTUL MakitoNaoiOP-332 (TUL) KazuakiMutaguchi

44 42110:3011:305 ESWL OP-333 DornierDeltaIIFarSight KanameAmedaOP-334 EdaptmsESWL ToshihikoMasagoOP-335 ECIRS TakuoAsaiOP-336 TULvsPNL YuichiroOiwaOP-337 Miniperc-PNL TakuroMasakiOP-338 PNL-CT- TakuyaOkusaOP-339 JunAsanoOP-340 HitoshiYamada

45 42113:3014:305 OP-341 NorihikoMasudaOP-342 AtsushiKomaru OP-343 TakeshiInoueOP-344 RAPNpentafecta YoshiharuKato

134

21


OP-345 Trifecta JunyaFurukawaOP-346 ArisaWadaOP-347 TakeshiNomuraOP-348 RyomaNishikawa

46 42114:3015:305 OP-349 3-portRAPN NaokazuIbukiOP-350 HidefumiKinoshitaOP-351 Flat4 KazuhideMakiyamaOP-

4月19日（木） - convention.co.jp · 4月19日（木）...

Documents

Transcript of 4月19日（木） - convention.co.jp · 4月19日（木）...